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Revision note VETMIC-D-13-8580 
 
ǯomments: 
 
Reviewer #1:  This manuscript is a composite of two topics - one that relates to an 
enhanced surveillance program in the UK for equine influenza virus (and presumably 
any other pathogens) and one that characterizes newer EIV isolates from various 
parts of the world.  I am not convinced that the two parts stand together very well.  If 
the surveillance program had resulted in the detection of novel EIV isolates that would 
have been missed in a passive surveillance model, then I could be convinced the two 
elements should be in the same manuscript.  However, there is no evidence that the 
enhanced program added anything to the detection of EIV in the period 
presented.  More samples were received but no connection was made to the isolates 
analyzed.  A "free" surveillance program is nice to have, but for the bulk of the world, it 
is not a program that is feasible with the economic resources available. 
 
We agree with the reviewer that there are two topics here. However, we also believe 
that they are closely linked and that the increase in diagnostic sample submission 
should be sufficient justification to include the strategies used to encourage 
practitioners to submit nasal swabs. In response, we have therefore deleted 
surveillance data from the results & discussion, but retained the approaches used in 
the method section, for reference purposes.  
 
The scheme only relates to equine influenza as the financial support we have from 
the HBLB only covers Ǯflu. This is considered the major threat to horse racing and 
breeding in the UK, due to its rapid spread in an unprotected population. 
 Ǯǯ
countries as well as the UK. We believe that for countries where funding could 
potentially be sought, this scheme provides examples of low-cost methods that can 
be used to improve surveillance & sample submission, such as Twitter. We fully ǯies. 
 
The isolate characterization data is certainly of value in monitoring the changes in 
EIV.  What is disappointing is that all of the work done so far does not seem able to 
predict when a new vaccine will be needed.  The antigenic mapping and serology tests 
tell us that changes are occurring and where in the HA and NA, but little about the 
efficacy of the current vaccines.  Field data still seems most reliable.  One wonders 
whether making ferret antisera in the future is worth the effort.  
 
The vaccine strain selection process for EIV, as described in previous publications, is 
loosely based on that for human influenza Ȃ i.e. four or more changes in HA1 amino 
acid sequence, affecting two or more antigenic sites (mapped for human H3) 
coupled with an 8-fold difference in HI titre using ferret sera. Unfortunately a lot 
more work needs to be done on antigenic characterisation of EIV as the antigenic 
sites have not yet been defined and we are still a long way off being able to predict 
Revision Note
when vaccine breakdown is likely to occur. An added complication is that, unlike 
human influenza vaccine production, the infrastructure does not exist to update 
equine vaccines within a year and the process typically takes 3-5 years. This makes 
it even more important to have an effective ǮǯǤ
system relies on monitoring changes in the field and attempting to predict when 
antigenically significant changes have occurred. Waiting for vaccine breakdown to 
occur in the field would not be ideal as the purpose of the OIE strain 
recommendations is to try and prevent this.  
 
Regarding the efficacy of current vaccines - as part of our work as an OIE reference ǡǮǯ
has proven more effective to maintain a good dialogue with all the vaccine 
manufacturers to encourage the regular updating of strains.  Politically, we also 
have to remain impartial. There is current evidence of vaccine breakdown in several 
countries, but we are not at liberty to report this in detail as the data does not 
belong to us, they are reported in outline by the OIE. The best we can do is to 
publish up to date sequence and antigenic data to make it clear that the Florida 
clade1 & clade2 viruses continue to diverge from vaccine strains in current use. 
 
Ferret sera have proven extremely useful at demonstrating antigenic changes in 
influenza viruses from humans and horses, equine sera are notoriously cross-
reactive and extremely expensive to produce. There are also Home Office & ethical 
implications for using companion animals for this process. Unpublished data from 
our group indicates that equine sera show very similar patterns of recognition 
compared to ferrets, but at a lower fold difference e.g. equine sera will show a 2-fold 
difference when ferrets may reach 4-16.  
 
Specific comments: 
1       Line 35.  This sentence sort of reflects the awkward transition from the 
surveillance discussion to real data.  My recommendation is to eliminate the 
surveillance material and focus on the isolates.  Perhaps a letter to Vet Record for the 
surveillance would be more appropriate. 
 
Surveillance material removed from abstract (and results section) 
 
2.      Line 103.   "considerable changes"  Somewhat subjective designation - when does 
"few" become considerable? 
 
ǮǯǮǯ. 
 
3.      Line 138.  Reference for "maximal sensitivity"? 
 
OIE terrestrial codes manual chapter 2.5.7 has been added to the references 
 
4.      Line 148.  Just curious what per cent of isolates are only detected on the 4th blind 
pass. 
 ǯǮǯǡ
assay to keep the number of passages to a minimum. None of our isolates since 
2006 have come up at P4 if negative at P3; if our samples are negative at P2 
they come up at P3 very rarely, but we routinely passage to P3 to be sure. 
 
5.      Line 167.  I will admit to being a poor statistician, but my impression was that 
geometric means are used on data sets when the range of serology values differ widely 
(4 -4048).  The HI titers probably vary by two-fold and a simple arithmetic average 
might be more correct (96 vs 91). 
 
Advice was originally taken from WHO experts who use GMT for human 
influenza virus HI tables. Titres for a given serum/antigen combination can 
vary by 2 fold in either direction, as the assay is based on serial two-fold 
dilutions, leading to a 4-fold variance in HI values which rarely reach above 
512. Our resident statistician agrees that GMT is the most appropriate method 
for this type of log2 data.  
 
6.      Line 230.  How many isolates came from the surveillance program? 
 
Surveillance data has been deleted from the manuscript. 
 
7.      Table 1 and Table X (no number and no reference in text but assume to be list of 
isolates from outside UK).   I would recommend putting these in "Supplementary data" 
as the information is of limited value other than the Genbank reference number. 
 
We disagree, for those working in the field of EIV, the outbreak information in 
Table 1 is of value.  Table 2 (outside the UK) has been transferred to 
supplementary data as requested as there is minimal information in this other 
than accession numbers.. 
 
8.      Figure 1.  As SA/4/03 is a vaccine strain, it should be included in this figure. 
 
SA/4/03 is highlighted in bold in the figure but may be easy to miss for those 
unfamiliar with the H3N8 tree. The figure legend has been altered to make 
this clear. 
 
9.      Figure 1 Legend.  Line 654.  Should there be a reference for the reassortant 
strains? Also Figure 4. 
 
The reassortant strains were identified in this manuscript, by sequencing NA, 
so there is no other reference available. The legends for figures 2 and 4 have 
been altered to make this clear. 
 
10.     Lines 300-303.  Data not shown? 
 
Text adjusted, to remove reference to this data.  
 
11.     Figure 3.  Lines 667-670.  Should the Figure have the a,b,c  label and if so, the 
legend does not match the figure - a and b are switched. Figure legend altered to 
remove reference to a/b/c. 
 
Figure legend has been altered to remove reference to a, b and c.  
 
12.     Figure 2.  Make clear distinction in figure between clade 1 and clade 2.  Should 
not have to refer to other figures to note where the clade switch occurs.  Same issue 
with Figure 5. 
 
Clade 1 and clade 2 labels have been added to the HA alignments (figure 2). 
Figure 5 has been labelled to show all the sublineages present (pre-
divergence, European, American, Florida clades 1 & 2)  
 
13.     Figure 7, Line 705.   Someone forgot to put A/equine/Richmond in the Fig.  Also, 
the larger spheres and larger squares are not evident in the copy of the Figure that 
downloaded.  Bit more attention to detail in the figure would be nice. 
 
An error was made by us and we submitted the wrong version of this figure 
with the original manuscript. The correct version has been inserted, 
Richmond/07 is shown in black, as described in the figure legend. Larger 
spheres are highlighted in a different colour (turquoise) so should be easy to 
distinguish. The sera indicated by larger squares have now been marked in 
heavy black and the remaining sera in grey to improve the contrast and 
should be evident in the figure provided. 
 
14.     Lines 409-410.  Statement is a bit vague about whether isolates actually came 
from the enhanced surveillance program. 
 
ǯǡamino acid 
differences between Florida clade 1 and 2 in 2003, which do not relate to the 
surveillance programme. 
 
15.     We seem to be left with the conclusion that none of the data were helpful in 
defining the next vaccine recommendations or perhaps the current vaccine is adequate 
for the viruses currently circulating. 
 
Text has been adjusted in the conclusion to clarify that current OIE 
recommendations are considered adequate. 
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Abstract 28 
Equine influenza viruses are a major cause of respiratory disease in horses worldwide and 29 
undergo antigenic drift. Several outbreaks of equine influenza occurred worldwide during 30 
2010-2012, including in vaccinated animals, highlighting the importance of surveillance and 31 
virus characterisation. To encourage submission of samples for isolation of current field 32 
strains, a sentinel practice scheme of over 180 equine practices was established in the UK. 33 
Virus isolates were characterisedobtained from more than 20 outbreaks over a 3-year period, 34 
including strains. Isolates were also submitted from the UK, Dubai, Germany and the USA. 35 
The haemagglutinin-1 (HA1) sequence of all isolates was determined and compared with 36 
OIE-recommended vaccine strains. Viruses from Florida clades 1 and 2 showed continued 37 
divergence from each other compared with 2009 isolates. The antigenic inter-relationships 38 
among viruses were determined using a haemagglutination-inhibition (HI) assay with ferret 39 
antisera and visualised using antigenic cartography. All European isolates belonged to 40 
Florida Clade 2, all those from the USA and Dubai belonged to Florida Clade 1. Two 41 
subpopulations of Clade 2 viruses were isolated, with either substitution A144V or I179V. 42 
Isolates from Dubai, obtained from horses shipped from Uruguay, belonged to Florida Clade 43 
1 and were similar to viruses isolated in the USA the previous year. The neuraminidase (NA) 44 
sequence of representative strains from 2007 and 2009 to 2012 was also determined and 45 
compared with that of earlier isolates dating back to 1963. Multiple changes were observed at 46 
the amino acid level and clear distinctions could be made between viruses belonging to 47 
Florida Clade 1 and Clade 2.  48 
 49 
Keywords: equine influenza virus, H3N8, surveillance, antigenic cartography, 50 
neuraminidase 51 
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Introduction 53 
Equine influenza virus (EIV) is a major cause of respiratory disease in horses and spreads 54 
rapidly between naïve animals. Although rarely fatal in otherwise healthy horses, EIV can 55 
cause severe disruption to the racing and breeding industries. It can also cause more severe 56 
clinical signs in animals with concurrent disease, such as hyperadrenocorticism, or in those 57 
under physiological stress.  58 
Influenza A viruses are subtyped according to their surface glycoproteins haemagglutinin 59 
(HA) and neuraminidase (NA). HA mediates virus entry, by binding to sialic acid receptors 60 
on the host cell surface and mediating fusion of viral and host membranes (Skehel & Wiley, 61 
2000). NA is involved in virus release from infected cells by cleaving sialic acid, it may also 62 
play a role in virus entry by allowing the virus to penetrate the mucus layer of the respiratory 63 
tract (Seto & Rott, 1966; Matrosovich et al, 2004).  64 
Two subtypes of influenza are known to have infected horses, H3N8 and H7N7. Equine 65 
H7N7 was first isolated in 1956, equine H3N8 emerged in 1963 and spread globally over the 66 
following two years. Between 1963 and the late 1970s both subtypes co-circulated in horses 67 
and reassortment occurred between them, indicating the occurrence of mixed infections (Ito 68 
et al, 1999). There have been isolated reports of seroconversions to H7N7 in unvaccinated 69 
animals, however virus of this subtype has not been isolated since 1979 and has been 70 
considered extinct for 20 years (0DGLü et al., 1996; Webster, 1993). During the 1980s the 71 
H3N8 subtype diverged into 2 sub-lineages, Eurasian and American (Daly et al., 1996). The 72 
American lineage has since been divided further into the Kentucky, South American and 73 
Florida sublineages (Lai et al., 2001). More recently, the Florida sub-lineage has diverged 74 
into two clades, based on HA sequence and antigenic differences (Bryant et al., 2009; Lewis 75 
et al., 2011). Between 2006 and 2009, Florida clade 2 was seen predominantly in Europe with 76 
 6 
 
occasional isolation of clade 1 strains in the UK and Ireland; in North America, recent 77 
isolates have all belonged to Clade 1 (Gagnon et al., 2007; Damiani et al., 2008; Bryant et al., 78 
2011; Gildea et al., 2012).  79 
Both clades have caused large outbreaks of equine influenza in the last 10 years. Examples 80 
include the UK in 2003 (Clade 2), Japan and Australia in 2007 (Clade 1), India in 2009 81 
(Clade 2), Mongolia and China from 2008 to 2009 (Clade 2) and most recently in several 82 
countries in South America during 2012 (Clade 1) (Newton et al., 2006; Callinan, 2008; Ito et 83 
al., 2008; Yamanaka et al., 2008; Virmani et al., 2010; OIE-WAHID interface).  84 
Vaccination is an effective method of control for equine influenza, providing protection by 85 
the induction of antibodies to viral surface glycoproteins, particularly HA. The role of 86 
antibodies to NA is unclear for EIV, however antibodies to human influenza NA are thought 87 
to contribute to protective immunity and neutralising titres correlate with reduced virus 88 
shedding in small animal models [Murphy et al., 1972; Brett & Johansson, 2005]. Like other 89 
influenza viruses, EIV undergoes antigenic drift and is able to evade antibody responses to 90 
divergent strains (Yates et al., 2000). Vaccine strains for equine influenza therefore need to 91 
be updated regularly and a formal process of vaccine strain selection is in place, overseen by 92 
the World Organisation for Animal Health (OIE). Genetic, antigenic and epidemiological 93 
data are considered prior to recommending changes to vaccine strains; current OIE 94 
recommendations are to include a representative of both Florida clade 1 and clade 2 viruses. 95 
To date, genetic and antigenic characterisation for selection of vaccine strains has focussed 96 
solely on the HA glycoprotein and antigenic drift in NA has been largely ignored.  97 
Our aim was to improve the monitoring of field strains of EIV. Here we describe the 98 
establishment of a surveillance programme for EIV in the UK, to encourage the submission 99 
of equine nasal swab samples. We present the HA1 sequences and antigenic characterisation 100 
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of recent field strains from the UK, Dubai, Germany and USA and compare them with 101 
current OIE vaccine strain recommendations. We show that the Florida cladeClade 1 and 102 
cladeClade 2 viruses have diverged further since the OIE recommendation to include both in 103 
commercial vaccines. We also show that multipleconsiderable changes have occurred within 104 
the NA gene segment of equine influenza H3N8 viruses since 1963.  105 
106 
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Methods 107 
Sentinel practice scheme 108 
An invitation letter was sent to 60 veterinary practices with equine practitioners within the 109 
UK.  Further practices were recruited to the scheme by invitation following submission of 110 
samples to the diagnostic laboratories at the Animal Health Trust (AHT). Participants were 111 
offered free diagnostic testing for samples from equids with suspected influenza, either nasal 112 
swabs or paired serum samples. A telephone helpline and dedicated website 113 
(www.equiflunet.org.uk) were also made available.  Sampling packs were sent to each 114 
contributing veterinary practice, including submission forms, virus transport medium and 115 
swabs. Newsletters were also distributed to keep participants informed of relevant 116 
information. All positive diagnoses were followed up by telephone contact to collect 117 
epidemiological data, including vaccination histories of affected animals. 118 
Diagnostic testing for presence of EIV 119 
Nasopharyngeal swabs were taken from horses showing signs of acute respiratory disease, or 120 
close contacts of affected animals. Swabs were placed in sterile tubes containing 5 mL virus 121 
transport medium (PBS containing 200 U/mL streptomycin, 150 U/mL penicillin, 5µg/mL 122 
fungizone (Gibco) and 600 µg/mL tryptone phosphate broth). All equine nasopharyngeal 123 
swabs sent to the AHT from 2010 to 2011 were then assayed by an in house nucleoprotein-124 
ELISA as described previously (Cook et al, 1988). Briefly, plates were coated with rabbit 125 
polyclonal serum against A/equine/Sussex/89 (H3N8), nasal swab extract was added to the 126 
plates and incubated for up to one hour. After washing, bound influenza antigen was detected 127 
by incubation with a monoclonal antibody to equine influenza virus nucleoprotein followed 128 
by anti-mouse peroxidase conjugated secondary antibody (Dako) and colorimetric assay. All 129 
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samples confirmed positive by NP ELISA were then subjected to RNA extraction and egg 130 
isolation as described below. Nasopharyngeal swabs sent to the AHT during 2012 were 131 
assayed by qRT-PCR as described previously (Bryant et al, 2010), using SensiFAST Probe 132 
Hi-ROX Onestep kit (Bioline) and a StepOne Plus qPCR instrument (Applied Biosystems). 133 
North American samples were tested by qRT-PCR (Lu et al, 2009) or by WKH'LUHFWLJHQ)OX134 
$WHVWNLW%'1HZ-HUVH\86$DFFRUGLQJWRWKHPDQXIDFWXUHU¶VGLUHFWLRQV 135 
Diagnostic serology assay  136 
The presence of antibodies to EIV in serum samples was determined by haemagglutination 137 
inhibition (HI) assay, using 1% chicken erythrocytes according to World Health Organisation 138 
standard procedures (WHO). For maximal sensitivity, sera were tested against Tween-treated 139 
viruses including A/equine/Prague/56 [H7N7], A/equine/Miami/63 [H3N8] and 140 
A/equine/Newmarket/2/93 [H3N8] (OIE 2012).]. Where possible, paired serum samples 141 
taken 14 days apart were analysed.   142 
Virus isolation in eggs 143 
Virus isolation was attempted from all swabs that were diagnosed positive by NP ELISA or 144 
qRT-PCR. Briefly, 0.1 ml each swab extract was inoculated into the allantoic cavity of two 145 
10-day-ROGIHUWLOL]HGKHQ¶VHJJVDWQeat, 10-1 and 10-2 dilutions and incubated at 34°C. Three 146 
days later, eggs were chilled at 4ºC overnight, allantoic fluid harvested and a 147 
haemaglutination (HA) assay performed to assess virus growth. Swabs giving a negative 148 
result after one round in eggs were passaged up to 3 times, checking for growth at each step 149 
to minimise the final number of passages. Working stocks were generated from virus isolates 150 
by inoculation of eggs at a 10-4 dilution, to reduce the risk of generating defective interfering 151 
particles. For most EIV strains, this was equivalent to approximately 10 to 100 EID50 per egg.  152 
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Antigenic characterisation by HI assay 153 
Ferret antisera were raised against representative strains by intranasal instillation of 0.1 ml 154 
EIV per nostril, equivalent to a final dose of 2x106 EID50. Sera were collected three weeks 155 
post-infection and stored at -20°C. Prior to use, 300 µl each antiserum was incubated with 156 
600 µl 0.38% potassium periodate for 15 min at room temperature, then 300 µl 3% glycerol-157 
PBS was added and the mixture incubated for a further 15 min at room temperature before 158 
heat-inactivation at 56°C for 30 min. Equine antisera from AHT archives were raised by 159 
aerosol challenge of Welsh mountain ponies and collected at least two weeks post-infection, 160 
those against American strains were supplied by the Gluck Equine Research Center and 161 
generated in the same manner from mixed-breed ponies. Equine sera were treated as 162 
described for ferret. HI assays were carried out using a 96-well format, according to standard 163 
procedures (WHO). Briefly, viruses were diluted to 4 HA units in a volume of 25 µl and 164 
back-titrated to ensure accuracy. Two-fold serial dilutions of each ferret serum were prepared 165 
in PBS and incubated with virus for 30-PLQDWURRPWHPSHUDWXUHWKHQȝORIFKLFNHQ166 
erythrocytes added. Samples were incubated at 4°C for 45 min prior to scoring. HI assays 167 
were carried out at least twice and geometric means calculated. Isolates from different years 168 
were grouped in separate batches, but each batch was run against the full panel of reference 169 
antigens to allow comparison of data. Quantitative analyses of the ferret HI data were 170 
performed using antigenic cartography, as described previously for human H3N2 and equine 171 
H3N8 viruses (Smith et al., 2004; Lewis et al, 2011). 172 
RNA extraction, RT PCR and sequencing 173 
RNA was extracted from all ELISA-positive swabs using a QIAamp viral RNA mini kit 174 
4LDJHQ DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQs. A 2-step PCR protocol was used, 175 
comprising a reverse transcription (RT) step using uni-12 primer, ¶-AGCGAAAGCAGG-¶ 176 
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and SuperScript II Reverse Transciptase from Invitrogen followed by PCR with either HA1-177 
VSHFLILF SULPHUV ¶-GCGAGCGAAAGCAGGGG-¶ DQG ¶-178 
GCGGATTTGCTTTTCTGGTAC-¶ RU 1$-VSHFLILF SULPHUV ¶-179 
AGCAAAAGCAGGAGTTT-¶ DQG ¶-AACTCCTTGTTTCTACT-¶ 7KH 3&5 SURWRFRO180 
consisted of an initial denaturation step of 92oC for 5 minutes followed by 30 cycles of 95oC 181 
for 1 minute, 50oC for 1.5 minutes and 72oC for 5.5 minutes. PCR products were separated 182 
by gel electrophoresis using a 1% agarose gel and visualised with GelRed (Biotium). PCR 183 
SURGXFWVZHUHSXULILHGXVLQJNLWVVXSSOLHGE\4LDJHQRU%LROLQHDFFRUGLQJWRPDQXIDFWXUHU¶V184 
recommendations. PCR products were sequenced using ABI BigDye® Terminator v3.1 185 
$SSOLHG %LRV\VWHPV DFFRUGLQJ WR PDQXIDFWXUHU¶V LQVWUXFWLRQV RQ DQ $%, 35,60 186 
Genetic Analyzer (Applied Biosystems).  187 
Sequence analysis and Phylogenetic trees 188 
Nucleotide sequences were visualized and edited using Seqman II version 5.03 (DNAstar 189 
Inc) and BioEdit (Ibis Pharmaceuticals Inc.). All sequences were deposited with Genbank. 190 
Nucleotide sequences were aligned to representative reference panels for HA1 or NA 191 
obtained from Genbank using ClustalW2 (EMBL-EBI). Derived amino acid sequences were 192 
aligned against representative strains from each sublineage of EIV, including pre-divergence, 193 
Eurasian, American (Kentucky), Florida Clades 1 and 2. Maximum-likelihood (ML) 194 
phylogenetic trees for the nucleotide sequences encoding HA1 (1009 nt) and NA (1410 nt) 195 
were created using PhyML version 3 (Guindon et al., 2009). Amino acid alignments were 196 
generated separately for isolates compared against A/equine/Richmond/1/07 using BioEdit 197 
version 7.0.5.3 (Ibis Pharmaceuticals Inc.). 198 
 199 
200 
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Results 201 
Establishment of sentinel practice scheme & rapid notification systems 202 
To encourage the submission of equine nasal swab and paired blood samples from suspected 203 
cases of equine influenza, a sentinel practice scheme was established at the Animal Health 204 
Trust. The aim was to recruit equine practitioners that were likely to see unvaccinated horses 205 
in the UK, rather than Thoroughbred and other high level competition horses, as these were 206 
the most likely to provide samples for virus isolation. The initial approach of 60 equine 207 
practices, which excluded those known to have clients primarily with Thoroughbreds, 208 
recruited 23 participants to the scheme. Over a period of 6 years, over 150 additional 209 
practices were recruited by several approaches: follow up from submission of samples to the 210 
AHT diagnostic service, distribution of newsletters or leaflets, recommendation by other 211 
participants or equine specialists, contact via the Equiflunet website 212 
(www.equiflunet.org.uk), or unsolicited requests. At the close of 2012, 188 veterinary 213 
practices were registered to the scheme and 84 submitted samples during that year. The 214 
number of veterinary surgeons from each practice contributing to the scheme ranged from 1 215 
WR7R LPSURYHFRPPXQLFDWLRQRI LQIOXHQ]DRXWEUHDNV WRHTXLQHSUDFWLWLRQHUV WKH µ7HOO-216 
7DLO¶ UDSLGQRWLILFDWLRQ V\VWHP ZDVGHYHORSHG Ln collaboration with Merial Animal Health. 217 
Any positive diagnoses were submitted to Merial by email and a text message sent to all 218 
YHWHULQDU\ VXUJHRQV ZKR KDG UHJLVWHUHG IRU WKH VFKHPH $Q µ(TXLIOXQHW¶ 7ZLWWHU DFFRXQW219 
(@equiflunet) was also established for instant notification of outbreaks of equine influenza 220 
and messages were captured by a feed system linked to the Equiflunet website.  221 
Outbreaks and sample submission: 2010 to 2012 222 
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Equine influenza outbreaks within the UK that were diagnosed from either nasal swabs or 223 
paired serum samples between January 2010 and December 2012 are summarised in Table 1. 224 
Twenty one counties were affected in England, Wales and Scotland with multiple outbreaks 225 
in some areas. The number of samples submitted per year via the sentinel practice scheme 226 
increased during this period, from 119 in 2010 to 251 in 2012. During 2010, a total of 894 227 
samples were sent to the AHT for diagnosis by NP-ELISA, 389 samples were sent in for 228 
serological testing by haemagglutination inhibition (HI) assay and 2 samples were sent for 229 
single radial haemolysis assay (SRH) assay. Of the samples sent, only 61 were submitted via 230 
the sentinel practice scheme for NP ELISA and 58 for HI testing. Of a total of 16 positive 231 
nasal swabs, virus was successfully isolated from 14; 2 horses were diagnosed positive by HI 232 
assay. 233 
During 2011, 650 nasal swab samples were submitted, 202 serum samples for HI assay and 3 234 
for SRH testing. Of those tested, 132 samples were submitted through the sentinel practice 235 
scheme, comprising 12 blood or serum samples for HI assay and 120 nasal swab samples for 236 
ELISA. Ten nasal swabs were diagnosed positive by ELISA, submitted from 7 premises in 237 
the UK. Of these, 8 viruses were isolated successfully in eggs. HA1 nucleotide sequence was 238 
obtained from 9 samples, either directly from the swab, egg isolated virus or both. Two 239 
horses were diagnosed positive by HI assay of paired sera during 2011.  None of the samples 240 
submitted during 2011 came from horses known to have been vaccinated recently.  241 
 242 
During 2012, very few samples were diagnosed positive from the UK until November. 243 
During the year, 427 nasal swab samples were submitted and 200 sera. Of these, 113 nasal 244 
swabs and 138 blood samples were sent in via the sentinel practice scheme; 12 were positive 245 
by NP ELISA, qPCR or HI assay. Seven viruses were isolated in eggs at first or second 246 
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passage. In addition to samples submitted from the UK, 17 virus isolates obtained between 247 
2010 and 2012 were received from the Gluck Equine Research Center, OIE reference 248 
laboratory for equine influenza in the USA (supplementary data).. Outbreaks in the USA 249 
were reported from 6 states in 2010, 10 states in 2011 and 17 in 2012, many of which were 250 
described by Pusterla et al. (2011) and subsequent work by that group. During 2011 and 251 
2012, there were also outbreaks of equine influenza reported in Germany, including cases in 252 
vaccinated animals. One isolate from 2012 was submitted to the AHT by the OIE reference 253 
laboratory for Germany, for antigenic characterisation. Three virus isolates were also 254 
submitted from the Central Veterinary Laboratories, Dubai, following an outbreak in a 255 
quarantine facility. The source of infection was a group of endurance horses transported from 256 
Uruguay to Dubai, consistent with reports to the OIE of extensive outbreaks of equine 257 
influenza affecting around 2,500 horses in Uruguay during 2012. The endurance horses had 258 
UHFHLYHG D SULPDU\ FRXUVH RI WZR GRVHV RI YDFFLQH DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V259 
recommendations. 260 
Genetic analyses - HA 261 
HA1 sequences were obtained from all virus isolates, plus one swab sample from which virus 262 
could not be isolated (East Renfrewshire/1/11). For most isolates, sequence was also 263 
determined directly from the nasal swab extract. In all instances, the HA1 nucleotide 264 
sequence obtained from both egg isolate and swab extract was identical, suggesting that no 265 
significant selection had occurred during egg passage. Phylogenetic analysis was carried out 266 
for the recent isolates against a panel of 130 equine H3N8 HA1 nucleotide sequences from 267 
GenBank. The resulting analysis grouped the viruses into 5 well-defined clusters, 268 
corresponding to the Pre-divergent, Eurasian, American and Florida clade 1 and 2 269 
sublineages (Figure 1). These clusters were each supported by high bootstrap values, ranging 270 
Formatted: Font: Times New
Roman
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from 97 to 100 after 100 replicates. All viruses isolated in the UK between 2010 and 2012 271 
belonged to the Florida clade 2 sublineage, all those characterised from the USA were of the 272 
Florida clade 1 sublineage. The strains from Dubai were most similar to clade 1 isolates from 273 
Kentucky 2011. Derived amino acid sequences were aligned against the current OIE 274 
recommended strain for Florida clade 2 (A/equine/Richmond/1/07), shown in Figure 2. In the 275 
alignment, each strain is representative of multiple isolates with identical HA1 sequences. 276 
The Florida clade 2 viruses appeared to have 3 consistent  amino acid substitutions compared 277 
to Richmond/1/07, two of which were P103L and V112I (Figure 2). A further substitution, 278 
E291D, was observed between Richmond/1/07 and all of the other strains described here; this 279 
was shared by all the clade 2 viruses isolated in the UK during 2007 (Bryant et al, 2009). 280 
Two different sub-populations were isolated in the UK during the period studied here, those 281 
with an additional change at position 144 and those with a substitution at 179, which was also 282 
observed in recent isolates from France and Germany. Amongst the American clade 1 283 
viruses, three amino acid substitutions were unique to 2010 isolates from California: D31N, 284 
T163I and I230V. There were 5 consistent amino acid changes between the current clade 1 285 
OIE-recommended strain (South Africa/4/03) and isolates from 2009 onwards: G7D, R62K, 286 
D104N, A138S and V223I. The HA2 sequence for some of the isolates was also determined 287 
which revealed amino acid substitutions between the recommended vaccine strains and the 288 
most recent Florida clade 1 and 2 viruses (data not shown). These substitutions in HA2 289 
included N169S and L187M between Richmond/1/07 and clade 2 isolates, and I198V 290 
between South Africa/4/03 and the clade 1 isolates. There were five amino acid substitutions 291 
in HA2 between the most recent clade 2 and clade 1 isolates (T43A, E50G, N169S, L187M 292 
and I198V). 293 
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The conserved amino acid substitutions between the Florida clade 1 and Florida clade 2 294 
viruses were mapped to the structure of the trimeric HA molecule, using A/duck/Ukraine/68 295 
[H3N8] PDB 1MQL (Ha et al, 2003), shown in Figure 3. Four differences mapped to the top 296 
of the molecule, close to the receptor binding site, with a further 12 mapping on the surface 297 
of the molecule. For comparison, the differences between the clade 2 viruses and the OIE 298 
recommended strain Richmond/1/07 and the clade 1 viruses and the recommended strain 299 
South Africa/4/03 are also shown. The clade 1 versus clade 2 comparison shows multiple 300 
differences between strains, whereas the OIE-recommended strain for each clade shows only 301 
one or two differences on the top of the HA molecule. The clade 2 versus American vaccine 302 
strains comparison shows a large number of differences between strains, including a ring of 303 
substitutions at the top of the molecule around the receptor binding site and multiple changes 304 
further down the molecule. 305 
Genetic analyses ± NA 306 
To investigate the level of variation in NA amongst circulating strains, the nucleotide 307 
sequence of segment 6 was determined for 19 strains isolated between 2010 and 2012 from 308 
the UK, USA, Germany and Dubai, as well as representative clade 1 and 2 isolates from 2007 309 
and 2009. Phylogenetic analyses were carried out as described for HA, using a panel of 99 310 
sequences from Genbank from 1963 to 2011 (Figure 4). The topology of the NA tree was 311 
similar to that of HA and separation of viruses belonging to Florida clades 1 and 2 was well-312 
supported with a bootstrap value of 98%. Major clades also correlated with significant 313 
country-wide outbreaks in 1979, 1989, 2003 and 2007. Three recent Florida clade 1 isolates, 314 
(Dorset/09, Lanarkshire/09 and Yorkshire/3/09) had an NA segment that was more similar to 315 
those of the clade 2 viruses and one Florida clade 2 isolate (Perthshire/1/09) had an NA more 316 
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similar to those of clade 1 viruses, indicating that reassortment had taken place between clade 317 
1 and clade 2. These isolates are highlighted in Figure 4.  318 
 319 
Derived amino acid sequences were aligned against representative strains from four major 320 
clades identified by phylogenetic analysis and are shown in Figure 5. Multiple amino acid 321 
substitutions were observed between sublineages with signature substitutions readily 322 
identified for the current Florida clade 1 and clade 2 viruses compared with the older 323 
American strains. There were 16 amino acid substitutions between the most recent UK 324 
isolates from clade 1 and clade 2. The majority of changes occurred within the first 80 325 
residues, including the membrane anchor sequence and stalk region of NA; these are not 326 
included in the protein structure solved for various subtypes of NA. For the purpose of 327 
structure mapping, the amino acid numbering of the predicted ectodomain was adjusted to 328 
correspond to that present in the H5N1 and H3N8 NA protein structure database files 2HTY 329 
and 2HT5. Multiple changes occurred on the surface of NA, shown mapped on the tetrameric 330 
structure of H5N1 (Figure 6), affecting both the distal and proximal surfaces of the molecule. 331 
An additional substitution V147I within the 150 loop was observed in equine viruses from 332 
the Japanese and Australian outbreak in 2007.  333 
Antigenic characterisation 334 
Low passage virus isolates were characterised by HI assay using post infection ferret antisera 335 
raised against eight representative EIV strains and the homologous reference strains. Sera 336 
included those raised against representatives from relevant sublineages [American 337 
(Kentucky), Florida clade 1, Florida clade 2], current UK vaccine strains and OIE 338 
recommended strains, as indicated in Table 2. All virus isolates raised low titres against the 339 
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European sera (data not shown), as expected from their genetic characterisation.  Ferret 340 
antisera against the American Kentucky lineage vaccine strains Newmarket/1/93 and 341 
Kentucky/98 recognised the Florida clade 2 isolates from 2010 to 2012, but gave a slightly 342 
lower titre than against homologous strains. They typically showed a 2-fold difference for 343 
Kentucky/98 and 2- to 4-fold lower titre for Newmarket/1/93. These sera recognised the 344 
Florida clade 1 viruses poorly, with most strains showing a 16- to 64- fold reduction against 345 
Newmarket/1/93 and an 8- to 16-fold lower titre against Kentucky/98 compared to 346 
homologous antigen. Ferret antisera were raised against the early representative of the Florida 347 
clade 2 viruses, Kentucky/97, which has sequence similarity to the older American strains, 348 
and outbreak strains Newmarket/5/03 and Richmond/1/07 (the current OIE-recommended 349 
clade 2 strain). These sera all recognised the clade 2 isolates from 2010 to 2012 and in most 350 
instances, to at least the same level as their respective homologous strains. None of the sera 351 
raised the maximum titre against their homologous strains; this was particularly noticeable 352 
for Kentucky/97 (Table 2).  Most of the clade 2 field isolates gave a 2- to 4-fold higher titre 353 
than Kentucky/97. All three of the antisera raised to clade 2 viruses gave lower titres against 354 
the clade 1 isolates from 2010 to 2012 than the clade 2 strains, reflecting the genetic 355 
differences between the two groups. Three sera were raised against clade 1 strains, including 356 
South Africa/4/03, one of the current OIE recommended strains for vaccines. The reciprocal 357 
pattern was seen with these sera, all sera recognised the clade 1 field isolates with high titres 358 
but with lower titres against the clade 2 strains. In both directions, 8- to 16-fold differences in 359 
titre were common suggesting antigenic divergence between the two clades.  360 
Antigenic cartography 361 
The antigenic relationships between 44 equine influenza A(H3N8) viruses, including the 362 
recent isolates described above and a reference panel of representative Florida clade 1 and 363 
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clade 2 strains are shown in Figure 7. The viruses grouped into two distinct antigenic clusters, 364 
with all the Florida clade 2 isolates falling into the blue cluster and all the clade 1 isolates 365 
grouping together in the red cluster. This is consistent with our previous findings, showing 366 
that the two phylogenetic clades were antigenically distinct (Lewis et al, 2011). The current 367 
recommended vaccine strains, A/equine/Richmond/1/07 and A/equine/South Africa/4/03, for 368 
either clade were located within their respective clusters and the antigenic distance between 369 
each isolate and the representative strain did not exceed 2.1 antigenic units, equivalent to a 4-370 
fold difference in HI titre. When we measured the antigenic distances from ferret sera raised 371 
to current and previous OIE-recommended strains for the Clade 2 cluster, we found that on 372 
average, currently circulating strains were 1.5 antigenic units from the 373 
A/equine/Richmond/1/2007 serum, but on average 2 antigenic units from a previously 374 
recommended vaccine strain, A/equine/Newmarket/1/1993 serum. 375 
 376 
HI of strains against Richmond and South Africa equine sera 377 
To determine whether the antigenic differences between strains belonging to the American, 378 
Florida cladeClade 1 and Florida cladeClade 2 sublineages could be distinguished by equine 379 
sera, HI assays were carried out against a panel of post-infection equine sera for a 380 
representative selection of strains from the three groups (Table 3). Compared with ferret sera, 381 
the titres were lower for equine sera, with homologous titres only reaching 128 rather than up 382 
to 1024. The two American sera showed lower titres against viruses from both of the Florida 383 
sublineages than the American strains; the antiserum raised against the older strain 384 
Kentucky/91 raised even lower titres than Kentucky/99. Although differences were subtle, 385 
these sera appeared to recognise the cladeClade 1 strains better than cladeClade 2, in contrast 386 
to ferret sera raised against similar strains (Table 2).  387 
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Of the sera raised against more recent viruses, both sera from Richmond/1/07-infected ponies 388 
recognised all three groups of viruses, with no more than a 2-fold difference in titre between 389 
field isolates and Richmond/1/07. The results for the South Africa cladeClade 1 sera were 390 
slightly different, with the highest titres raised against homologous or very closely related 391 
cladeClade 1 viruses. Differences in HI titre within this group of viruses were less than 2-fold 392 
compared with the homologous titre for South Africa/4/03. However, the cladeClade 1 sera 393 
consistently raised lower HI titres against both American and cladeClade 2 viruses, giving 394 
differences of 2- to 4-fold compared with the South Africa/4/03 strain. 395 
 396 
397 
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Discussion 398 
Equine influenza viruses belonging to the H3N8 subtype are thought to have crossed the 399 
species barrier from birds in the early 1960s and subsequently spread worldwide. They have 400 
continued to circulate since then, causing widespread outbreaks in naïve populations, such as 401 
South Africa in 2003 and Australia in 2007, but also occasionally in vaccinated horses. 402 
Extensive outbreaks in Europe in highly vaccinated horses in the late 1980s demonstrated 403 
that circulating equine influenza viruses had undergone significant antigenic drift from the 404 
strains included in vaccines and highlighted the need for effective surveillance programmes. 405 
Here we describe recent developments to the surveillance scheme established in the UK, 406 
based upon a network of sentinel practices from which equine samples were sent in for free 407 
diagnostic testing. A variety of media were used to communicate information with equine 408 
practitioners, including telephone, post, email, website and social media (Twitter, Tell-Tail). 409 
At least 10% of the practices submitted samples each year between 2006 and 2011 and 46% 410 
in 2012; live virus was recovered successfully every year, making antigenic characterisation 411 
of strains possible. 412 
In 2003, two large scale epidemics of equine influenza in the UK and South Africa led to the 413 
division of the Florida sublineage of equine influenza into two clades, 1 and 2. The original 414 
difference was based upon two amino acid substitutions within HA1 at positions 78 and 159, 415 
which were sufficient to cause an antigenic difference that was recognisable by ferret sera 416 
(OIE, 2008). Since then, the two clades have diverged further and we show here that there are 417 
now 9 consistent amino acid differences between viruses from the different groups isolated in 418 
2012 with a further 2 substitutions between subsets of the clade 2 viruses. Additional variants 419 
arose during this period as a result of reassortment between clade 1 and clade 2 viruses, 420 
which led to new combinations of HA and NA.  421 
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In 2010, the OIE recommended that vaccine manufacturers should include a representative of 422 
both Florida clade 1 and Florida clade 2 viruses (OIE 2010). Surveillance data reported here 423 
confirm that viruses from both clades continued to circulate, with viruses of Florida clade 1 424 
likely to be the cause of multiple large-scale outbreaks in South America. Clade 2 viruses 425 
predominated in Europe, causing outbreaks in the UK, France, Ireland and Germany. 426 
Surveillance data therefore support inclusion of both clades in vaccines for horses that travel 427 
between continents.  428 
Antigenic characterisation of the strains reported here indicated that representatives of the 429 
Florida clades 1 and 2 could be distinguished from each other readily, with differences 430 
ranging between 2- and 16-fold by HI. These results were comparable to those seen with 431 
viruses isolated in 2009 (Bryant et al., 2011), suggesting that the ferret model does not 432 
distinguish between viruses with HA1 molecules containing the most recent amino acid 433 
differences. These substitutions were primarily conservative changes, the notable exception 434 
being the P103L substitution seen in recent clade 2 viruses. However, this position is buried 435 
within the HA molecule and is not likely to affect the binding of ferret antisera. Similarly, 436 
ferret sera raised against Kentucky lineage vaccine strains from the 1990s continued to 437 
recognise Florida clade 2 viruses. However, there was typically a difference of 4-fold 438 
between the titres against the most recent clade 2 viruses from 2011 and 2012 compared with 439 
the homologous American reference strains Newmarket/1/93 and Kentucky/98, whereas 440 
some of those from 2010 showed only a 2-fold difference. Caution should be observed in 441 
interpretation of cross-reactive titres, as ferret sera to Newmarket/1/93 vaccine strain cross-442 
reacted well against the Newmarket/5/03 outbreak strain from the 2003 epidemic in the UK, 443 
however commercial vaccines containing this strain failed to protect against the outbreak 444 
strain (Newton et al., 2006). Cross-reaction was therefore a poor indicator of cross protection 445 
in this instance. Clade 1 ferret sera cross-reacted well against other members of the group and 446 
 23 
 
also recognised clade 2 viruses, but to a lower level.  Interestingly, equine sera raised against 447 
Richmond/1/07 reacted well against viruses belonging to all 3 sublineages whereas South 448 
Africa/4/03 did not react as well against the clade 2 viruses. This result suggests that 449 
Richmond/1/07 could make a good vaccine strain for protecting against both clade 1 and 450 
clade 2 viruses, with the caveat outlined above that cross-reaction does not necessarily 451 
correlate with cross-protection. Ideally, equine sera would be used for antigenic 452 
characterisation of equine influenza virus strains, however these sera are often broadly cross-453 
reactive making them insensitive to antigenic differences between strains. In our experience, 454 
the HI titres are often low and strains that give a 4- or 8-fold difference with ferret sera may 455 
only raise a 2-fold difference using equine sera, making interpretation difficult. 456 
To date, vaccine strain selection for EIV has focussed solely on HA genetic and antigenic 457 
differences and there is a lack of sequence data available for NA for recent isolates from 458 
Florida clade 2. Comparison of amino acid sequences shown here indicated that NA had 459 
undergone considerable divergence since 1963 and outbreak strains from 1979, 1989, 2003 460 
and 2007 had multiple amino acid changes compared with previous sublineages. Recent 461 
Florida clade 1 and clade 2 viruses differed by 16 or more amino acids and it was clear that 462 
reassortment had taken place in strains isolated in the UK. Multiple changes occurred within 463 
the stalk region of NA and so could not be mapped on the structure of the tetrameric head 464 
region of the NA; however changes also occurred on both the upper and lower surfaces of the 465 
head region, including regions close to the active site and within the C-terminal region where 466 
human sera have been shown to recognise epitopes in the NA of H5N1 viruses (Khurana et 467 
al., 2011). Also of interest was the V147I substitution observed in isolates from the 2007 468 
outbreaks in Japan and Australia. All other H3N8 viruses of avian or equine origin, with NA 469 
sequences currently available on Genbank, had valine at this position. The exceptions were 470 
the H3N8 canine isolates from the USA, which had isoleucine (data not shown). This 471 
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position is equivalent to V149 of the N1 structure and falls within the 150 loop of NA 472 
(Russell et al, 2006), an important region for NA activity (Lin et al. 2010). The conformation 473 
of this loop may affect the size of the adjacent 150 cavity, which potentially differs between 474 
group 1 and group 2 NAs.  475 
Further work is required to determine the role of antibodies to NA in immunity in the horse 476 
but they may contribute to vaccine efficiency and immune selection (Johansson et al., 1998).  477 
 478 
Conclusion 479 
Equine influenza Florida sublineage clade 1 and 2 viruses continued to cause 480 
outbreaks worldwide between 2010 and 2012. Clade 2 predominated in Europe while clade 1 481 
was isolated in North and South America. Sequence analysis of NA revealed that 482 
reassortment had occurred between the two clades and some virus isolates from 2009 had 483 
new combinations of HA and NA. The two sublineages have diverged further since 2009 and 484 
can be distinguished readily by antigenic analysis. Current OIE vaccine strain 485 
recommendations for representatives of Florida clade 1 and clade 2 remain adequate, based 486 
on antigenic differences determined by HI. 487 
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Tables  625 
Table 1. Outbreaks of EIV in the UK 2010 to 2012. 626 
Footnote: NPFC1- Florida sublineage clade 1 (A/eq/South Africa/4/03-like), FC2- 627 
Florida sublineage clade 2 (A/eq/Newmarket/5/03-like), ELISA ± nucleoprotein 628 
enzymeEnzyme linked immunosorbent assayImmunosorbent Assay, qPCR ± quantitative 629 
polymerase chain reaction, HI ± haemagglutination inhibition assay, HADirectigen ± BD 630 
diagnostics, Immunoassay ± Optical ImmunoAssay Kit, Viva Diagnostika,  HA1. Binax-Now 631 
± Binax,  HA1 Acc. ± Haemagglutinin 1 accession numbers, NA Acc. ± Neuraminidase 632 
accession numbers. 633 
 634 
Table 2. HI titres of EIV strains using ferret sera.  635 
Footnote: The lineage of new isolates is indicated on the left and ordered by isolation 636 
date. Homologous titres are shown in bold, titres for sera against strains from the same 637 
sublineage are highlighted in grey boxes. NewN/1/93 ± A/eq/Newmarket/1/93, N/2/93 ± 638 
A/eq/Newmarket/2/93, Ken/97 ± A/eq/Kentucky/97,      Ken/98 ± A/eq/Kentucky/98, 639 
NewN/5/03 ± A/eq/Newmarket/5/03, SA/4/03 ± A/eq/South Africa/4/03, RichRic/1/07 ± 640 
A/eq/Richmond/1/07, Lin/1/07 ± A/eq/Lincolnshire/1/07, Dor/09 ± A/eqequine/Dorset/09. 641 
Am ± American lineage, FC1 ± Florida sublineage clade 1, FC2 - Florida sublineage clade 2. 642 
 643 
Table 3. HI titres of EIV strains using post-infection equine sera. 644 
Footnote: The lineage of strains tested is indicated on the left. Titrestitres for sera 645 
against strains from the same sublineage are highlighted in grey boxes, homologous titres are 646 
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shown in bold. Ken/91 ± A/eqequine/Kentucky/91, Ken/99 - A/eqequine/Kentucky/99, 647 
Rich/07 - A/eqequine/Richmond/1/07, Ken/4/07 ± A/eq/Kentucky/4/07, SA/4/03 ± 648 
A/eq/South Africa/4/03. For Rich/07 and SA/4/03 antisera, numbers 1 and 2 relate to serum 649 
samples from pony 1 and pony 2 respectively. Am ± American lineage, FC1 ± Florida 650 
sublineage clade 1, FC2 - Florida sublineage clade 2. 651 
 652 
Supplementary data 653 
Table S1 Virus isolates from outside the UK: Genbank accession numbers. FC1 ± Florida 654 
sublineage clade 1, FC2 - Florida sublineage clade 2. 655 
656 
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Figure captions 657 
Figure 1  658 
HA Phylogenetic Tree 659 
Phylogenetic analysis of HA1 nucleotide sequences encoded by EIV. A maximum likelihood 660 
tree was created using PhyML version 3. Bootstrap values obtained after 100 replicates are 661 
shown at major nodes. Amino acid substitutions are indicated at branch points, or in brackets. 662 
Phylogenetic groups are shown by continuous bars on the right, as indicated. Accession 663 
numbers for the sequences reported in this manuscript are listed in Table 1. Sequences are 664 
coloured by date of isolation for the years 2010 (green), 2011 (red) and 2012 (blue) with the 665 
older isolates in black. Representative OIE-recommended vaccine strains 666 
A/eq/Richmond/1/07 and A/eq/South Africa/4/03 are shown in bold. Reassortant strains 667 
containing HA from one Florida clade and NA from the other, identified in this manuscript, 668 
are highlighted inReassortant strains are highlighted yellow. 669 
Figure 2 670 
Alignment of HA1 amino acid sequences. 671 
Derived amino acid differences in HA1 observed between representative field strains from 672 
Florida clade 2 and clade 1 isolated during 2010-2012 compared to 673 
A/eqequine/Richmond/1/07 (top). The sublineage of isolates is indicated on the left and 674 
ordered by isolation date. Residues are numbered from 1 to 329 starting with the serine 675 
residue downstream of the predicted signal peptide. Amino acid identity to 676 
A/eqequine/Richmond/1/07 is shown with a dot. Examples of strains from 2009 are included 677 
to allow comparison with Bryant et al (2011). 678 
 679 
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Figure 3 680 
HA structures. 681 
Location of the amino acid differences on the A/duck/Ukraine/1/63 H3 HA structure (Ha et 682 
al, 2003) between OIE recommended Florida clade 1 strain A/eq/South Africa/4/03 and 683 
2010-2012 clade 1 isolates,(a) OIE recommended Florida clade 2 strain 684 
A/eqequine/Richmond/1/07 and 2010-2012 clade 2 isolates and(b) OIE recommended Florida 685 
clade 1 strain A/equine/South Africa/4/03 and 2010-2012 clade 1 isolates (c) 2010-2012 686 
isolates from Florida clade 1 and clade 2. Established changes are shown in red, those that 687 
appeared in one year only are shown in blue. HA1 residues 112, 179, 230 and 251 are buried. 688 
HA1 residue 7 and HA2 residues 187 and 198 are not shown. 689 
Figure 4 690 
NA Phylogenetic Tree 691 
Phylogenetic analysis of NA nucleotide sequences encoded by EIV. A maximum likelihood 692 
tree was created using PhyML version 3. Bootstrap values obtained after 100 replicates are 693 
shown at major nodes. Amino acid substitutions are indicated at branch points, or in brackets. 694 
Phylogenetic groups are shown by continuous bars on the right, as indicated. Accession 695 
numbers for the sequences reported in this manuscript are listed in Table 1. Sequences are 696 
coloured by date of isolation for the years 2010 (green), 2011 (red) and 2012 (blue) with the 697 
older isolates in black. Representative OIE-recommended vaccine strains 698 
A/eq/Richmond/1/07 and A/eq/Ohio/03 (A/eq/South Africa/4/03-like) are shown in bold. 699 
Reassortant strains containing NA from one Florida clade and HA from the other, identified 700 
in this manuscript, are highlighted in yellow. 701 
 702 
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Figure 5 703 
Alignment of NA amino acid sequences. 704 
Derived amino acid differences in NA observed between representative strains from Pre-705 
divergent, American, Eurasian, Florida clade 12 and Florida clade 21 sublineages compared 706 
to A/eq/Miami/63 (top). The sublineage of isolates is indicated on the left and ordered by 707 
isolation date. Residues are numbered from 1 to 470 starting with the methionine residue at 708 
the start of the predicted signal peptide. The numbering has not been adjusted to correspond 709 
to N1 or N2 numbering. Amino acid identity to A/eq/Miami/63 is shown with a dot.  710 
 711 
Figure 6 712 
NA structure 713 
Location of the amino acid differences on the H5N1 NA structure (Russell et al., 2006) 714 
between (a) OIE recommended Florida clade 2 strain A/eqequine/Richmond/1/07 and 2010-715 
2012 clade 2 isolates, (b) OIE recommended Florida clade 1 strain A/eqequine/South 716 
Africa/4/03 and 2010-2012 clade 1 isolates, as well as (c) 2010-2012 isolates from Florida 717 
clade 1 and clade 2. Established changes are shown in red, those that appeared in one year 718 
only are shown in blue. 719 
Figure 7 720 
Antigenic cartography 721 
Antigenic map showing the relationships between virus strains isolated between 2010 and 722 
2012. Virus strains are shown as spheres, the positions of sera are shown as open boxes. The 723 
OIE-recommended vaccine strains are indicated in black (A/eqequine/South Africa/4/2003 & 724 
Formatted: Font: Font color: Auto,
English (U.K.)
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A/eqequine/Richmond/1/2007)  and their corresponding sera as larger squares; representative 725 
strains from clade 1 (A/eq/Lincolnshire/1equine/Lincoln/2007, A/eqequine/Dorset/200909),  726 
clade 2 (A/eqequine/Kentucky/199797, A/eqequine/Newmarket/5/2003) and current 727 
commercial vaccine strains(A/eqequine/Newmarket/1/199393, 728 
A/eqequine/Kentucky/199898) are highlighted  as larger spheres in turquoise. The scale bar 729 
indicates one antigenic unit, equivalent to a 2-fold difference in HI titre. 730 
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Abstract 28 
Equine influenza viruses are a major cause of respiratory disease in horses worldwide and 29 
undergo antigenic drift. Several outbreaks of equine influenza occurred worldwide during 30 
2010-2012, including in vaccinated animals, highlighting the importance of surveillance and 31 
virus characterisation. Virus isolates were characterised from more than 20 outbreaks over a 32 
3-year period, including strains from the UK, Dubai, Germany and the USA. The 33 
haemagglutinin-1 (HA1) sequence of all isolates was determined and compared with OIE-34 
recommended vaccine strains. Viruses from Florida clades 1 and 2 showed continued 35 
divergence from each other compared with 2009 isolates. The antigenic inter-relationships 36 
among viruses were determined using a haemagglutination-inhibition (HI) assay with ferret 37 
antisera and visualised using antigenic cartography. All European isolates belonged to 38 
Florida Clade 2, all those from the USA belonged to Florida Clade 1. Two subpopulations of 39 
Clade 2 viruses were isolated, with either substitution A144V or I179V. Isolates from Dubai, 40 
obtained from horses shipped from Uruguay, belonged to Florida Clade 1 and were similar to 41 
viruses isolated in the USA the previous year. The neuraminidase (NA) sequence of 42 
representative strains from 2007 and 2009 to 2012 was also determined and compared with 43 
that of earlier isolates dating back to 1963. Multiple changes were observed at the amino acid 44 
level and clear distinctions could be made between viruses belonging to Florida Clade 1 and 45 
Clade 2.  46 
 47 
Keywords: equine influenza virus, H3N8, surveillance, antigenic cartography, 48 
neuraminidase 49 
50 
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Introduction 51 
Equine influenza virus (EIV) is a major cause of respiratory disease in horses and spreads 52 
rapidly between naïve animals. Although rarely fatal in otherwise healthy horses, EIV can 53 
cause severe disruption to the racing and breeding industries. It can also cause more severe 54 
clinical signs in animals with concurrent disease, such as hyperadrenocorticism, or in those 55 
under physiological stress.  56 
Influenza A viruses are subtyped according to their surface glycoproteins haemagglutinin 57 
(HA) and neuraminidase (NA). HA mediates virus entry, by binding to sialic acid receptors 58 
on the host cell surface and mediating fusion of viral and host membranes (Skehel & Wiley, 59 
2000). NA is involved in virus release from infected cells by cleaving sialic acid, it may also 60 
play a role in virus entry by allowing the virus to penetrate the mucus layer of the respiratory 61 
tract (Seto & Rott, 1966; Matrosovich et al, 2004).  62 
Two subtypes of influenza are known to have infected horses, H3N8 and H7N7. Equine 63 
H7N7 was first isolated in 1956, equine H3N8 emerged in 1963 and spread globally over the 64 
following two years. Between 1963 and the late 1970s both subtypes co-circulated in horses 65 
and reassortment occurred between them, indicating the occurrence of mixed infections (Ito 66 
et al, 1999). There have been isolated reports of seroconversions to H7N7 in unvaccinated 67 
animals, however virus of this subtype has not been isolated since 1979 and has been 68 
considered extinct for 20 years (0DGLü et al., 1996; Webster, 1993). During the 1980s the 69 
H3N8 subtype diverged into 2 sub-lineages, Eurasian and American (Daly et al., 1996). The 70 
American lineage has since been divided further into the Kentucky, South American and 71 
Florida sublineages (Lai et al., 2001). More recently, the Florida sub-lineage has diverged 72 
into two clades, based on HA sequence and antigenic differences (Bryant et al., 2009; Lewis 73 
et al., 2011). Between 2006 and 2009, Florida clade 2 was seen predominantly in Europe with 74 
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occasional isolation of clade 1 strains in the UK and Ireland; in North America, recent 75 
isolates have all belonged to Clade 1 (Gagnon et al., 2007; Damiani et al., 2008; Bryant et al., 76 
2011; Gildea et al., 2012).  77 
Both clades have caused large outbreaks of equine influenza in the last 10 years. Examples 78 
include the UK in 2003 (Clade 2), Japan and Australia in 2007 (Clade 1), India in 2009 79 
(Clade 2), Mongolia and China from 2008 to 2009 (Clade 2) and most recently in several 80 
countries in South America during 2012 (Clade 1) (Newton et al., 2006; Callinan, 2008; Ito et 81 
al., 2008; Yamanaka et al., 2008; Virmani et al., 2010; OIE-WAHID interface).  82 
Vaccination is an effective method of control for equine influenza, providing protection by 83 
the induction of antibodies to viral surface glycoproteins, particularly HA. The role of 84 
antibodies to NA is unclear for EIV, however antibodies to human influenza NA are thought 85 
to contribute to protective immunity and neutralising titres correlate with reduced virus 86 
shedding in small animal models [Murphy et al., 1972; Brett & Johansson, 2005]. Like other 87 
influenza viruses, EIV undergoes antigenic drift and is able to evade antibody responses to 88 
divergent strains (Yates et al., 2000). Vaccine strains for equine influenza therefore need to 89 
be updated regularly and a formal process of vaccine strain selection is in place, overseen by 90 
the World Organisation for Animal Health (OIE). Genetic, antigenic and epidemiological 91 
data are considered prior to recommending changes to vaccine strains; current OIE 92 
recommendations are to include a representative of both Florida clade 1 and clade 2 viruses. 93 
To date, genetic and antigenic characterisation for selection of vaccine strains has focussed 94 
solely on the HA glycoprotein and antigenic drift in NA has been largely ignored.  95 
Our aim was to improve the monitoring of field strains of EIV. Here we describe the 96 
establishment of a surveillance programme for EIV in the UK, to encourage the submission 97 
of equine nasal swab samples. We present the HA1 sequences and antigenic characterisation 98 
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of recent field strains from the UK, Dubai, Germany and USA and compare them with 99 
current OIE vaccine strain recommendations. We show that the Florida clade 1 and clade 2 100 
viruses have diverged further since the OIE recommendation to include both in commercial 101 
vaccines. We also show that multiple changes have occurred within the NA gene segment of 102 
equine influenza H3N8 viruses since 1963.  103 
104 
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Methods 105 
Sentinel practice scheme 106 
An invitation letter was sent to 60 veterinary practices with equine practitioners within the 107 
UK.  Further practices were recruited to the scheme by invitation following submission of 108 
samples to the diagnostic laboratories at the Animal Health Trust (AHT). Participants were 109 
offered free diagnostic testing for samples from equids with suspected influenza, either nasal 110 
swabs or paired serum samples. A telephone helpline and dedicated website 111 
(www.equiflunet.org.uk) were also made available.  Sampling packs were sent to each 112 
contributing veterinary practice, including submission forms, virus transport medium and 113 
swabs. Newsletters were also distributed to keep participants informed of relevant 114 
information. All positive diagnoses were followed up by telephone contact to collect 115 
epidemiological data, including vaccination histories of affected animals. 116 
Diagnostic testing for presence of EIV 117 
Nasopharyngeal swabs were taken from horses showing signs of acute respiratory disease, or 118 
close contacts of affected animals. Swabs were placed in sterile tubes containing 5 mL virus 119 
transport medium (PBS containing 200 U/mL streptomycin, 150 U/mL penicillin, 5µg/mL 120 
fungizone (Gibco) and 600 µg/mL tryptone phosphate broth). All equine nasopharyngeal 121 
swabs sent to the AHT from 2010 to 2011 were then assayed by an in house nucleoprotein-122 
ELISA as described previously (Cook et al, 1988). Briefly, plates were coated with rabbit 123 
polyclonal serum against A/equine/Sussex/89 (H3N8), nasal swab extract was added to the 124 
plates and incubated for up to one hour. After washing, bound influenza antigen was detected 125 
by incubation with a monoclonal antibody to equine influenza virus nucleoprotein followed 126 
by anti-mouse peroxidase conjugated secondary antibody (Dako) and colorimetric assay. All 127 
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samples confirmed positive by NP ELISA were then subjected to RNA extraction and egg 128 
isolation as described below. Nasopharyngeal swabs sent to the AHT during 2012 were 129 
assayed by qRT-PCR as described previously (Bryant et al, 2010), using SensiFAST Probe 130 
Hi-ROX Onestep kit (Bioline) and a StepOne Plus qPCR instrument (Applied Biosystems). 131 
North American samples were tested by qRT-PCR (Lu et al, 2009) or by WKH'LUHFWLJHQ)OX132 
A test kit (BD, New Jersey86$DFFRUGLQJWRWKHPDQXIDFWXUHU¶VGLUHFWLRQV 133 
Diagnostic serology assay  134 
The presence of antibodies to EIV in serum samples was determined by haemagglutination 135 
inhibition (HI) assay, using 1% chicken erythrocytes according to World Health Organisation 136 
standard procedures (WHO). For maximal sensitivity, sera were tested against Tween-treated 137 
viruses including A/equine/Prague/56 [H7N7], A/equine/Miami/63 [H3N8] and 138 
A/equine/Newmarket/2/93 [H3N8] (OIE 2012). Where possible, paired serum samples taken 139 
14 days apart were analysed.   140 
Virus isolation in eggs 141 
Virus isolation was attempted from all swabs that were diagnosed positive by NP ELISA or 142 
qRT-PCR. Briefly, 0.1 ml each swab extract was inoculated into the allantoic cavity of two 143 
10-day-old fertilized KHQ¶VHJJVDWQeat, 10-1 and 10-2 dilutions and incubated at 34°C. Three 144 
days later, eggs were chilled at 4ºC overnight, allantoic fluid harvested and a 145 
haemaglutination (HA) assay performed to assess virus growth. Swabs giving a negative 146 
result after one round in eggs were passaged up to 3 times, checking for growth at each step 147 
to minimise the final number of passages. Working stocks were generated from virus isolates 148 
by inoculation of eggs at a 10-4 dilution, to reduce the risk of generating defective interfering 149 
particles. For most EIV strains, this was equivalent to approximately 10 to 100 EID50 per egg.  150 
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Antigenic characterisation by HI assay 151 
Ferret antisera were raised against representative strains by intranasal instillation of 0.1 ml 152 
EIV per nostril, equivalent to a final dose of 2x106 EID50. Sera were collected three weeks 153 
post-infection and stored at -20°C. Prior to use, 300 µl each antiserum was incubated with 154 
600 µl 0.38% potassium periodate for 15 min at room temperature, then 300 µl 3% glycerol-155 
PBS was added and the mixture incubated for a further 15 min at room temperature before 156 
heat-inactivation at 56°C for 30 min. Equine antisera from AHT archives were raised by 157 
aerosol challenge of Welsh mountain ponies and collected at least two weeks post-infection, 158 
those against American strains were supplied by the Gluck Equine Research Center and 159 
generated in the same manner from mixed-breed ponies. Equine sera were treated as 160 
described for ferret. HI assays were carried out using a 96-well format, according to standard 161 
procedures (WHO). Briefly, viruses were diluted to 4 HA units in a volume of 25 µl and 162 
back-titrated to ensure accuracy. Two-fold serial dilutions of each ferret serum were prepared 163 
in PBS and incubated with virus for 30-PLQDWURRPWHPSHUDWXUHWKHQȝORIFKLFNHQ164 
erythrocytes added. Samples were incubated at 4°C for 45 min prior to scoring. HI assays 165 
were carried out at least twice and geometric means calculated. Isolates from different years 166 
were grouped in separate batches, but each batch was run against the full panel of reference 167 
antigens to allow comparison of data. Quantitative analyses of the ferret HI data were 168 
performed using antigenic cartography, as described previously for human H3N2 and equine 169 
H3N8 viruses (Smith et al., 2004; Lewis et al, 2011). 170 
RNA extraction, RT PCR and sequencing 171 
RNA was extracted from all ELISA-positive swabs using a QIAamp viral RNA mini kit 172 
4LDJHQ DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV $ -step PCR protocol was used, 173 
comprising a reverse transcription (RT) step using uni-12 primer, ¶-AGCGAAAGCAGG-¶ 174 
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and SuperScript II Reverse Transciptase from Invitrogen followed by PCR with either HA1-175 
VSHFLILF SULPHUV ¶-GCGAGCGAAAGCAGGGG-¶ DQG ¶-176 
GCGGATTTGCTTTTCTGGTAC-¶ RU 1$-VSHFLILF SULPHUV ¶-177 
AGCAAAAGCAGGAGTTT-¶ DQG ¶-AACTCCTTGTTTCTACT-¶ 7KH 3&5 SURWRFRO178 
consisted of an initial denaturation step of 92oC for 5 minutes followed by 30 cycles of 95oC 179 
for 1 minute, 50oC for 1.5 minutes and 72oC for 5.5 minutes. PCR products were separated 180 
by gel electrophoresis using a 1% agarose gel and visualised with GelRed (Biotium). PCR 181 
SURGXFWVZHUHSXULILHGXVLQJNLWVVXSSOLHGE\4LDJHQRU%LROLQHDFFRUGLQJWRPDQXIDFWXUHU¶V182 
recommendations. PCR products were sequenced using ABI BigDye® Terminator v3.1 183 
$SSOLHG %LRV\VWHPV DFFRUGLQJ WR PDQXIDFWXUHU¶V LQVWUXFWLRQV RQ DQ $%, 35,60 184 
Genetic Analyzer (Applied Biosystems).  185 
Sequence analysis and Phylogenetic trees 186 
Nucleotide sequences were visualized and edited using Seqman II version 5.03 (DNAstar 187 
Inc) and BioEdit (Ibis Pharmaceuticals Inc.). All sequences were deposited with Genbank. 188 
Nucleotide sequences were aligned to representative reference panels for HA1 or NA 189 
obtained from Genbank using ClustalW2 (EMBL-EBI). Derived amino acid sequences were 190 
aligned against representative strains from each sublineage of EIV, including pre-divergence, 191 
Eurasian, American (Kentucky), Florida Clades 1 and 2. Maximum-likelihood (ML) 192 
phylogenetic trees for the nucleotide sequences encoding HA1 (1009 nt) and NA (1410 nt) 193 
were created using PhyML version 3 (Guindon et al., 2009). Amino acid alignments were 194 
generated separately for isolates compared against A/equine/Richmond/1/07 using BioEdit 195 
version 7.0.5.3 (Ibis Pharmaceuticals Inc.). 196 
 197 
198 
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Results 199 
Outbreaks and sample submission: 2010 to 2012 200 
Equine influenza outbreaks within the UK that were diagnosed from either nasal swabs or 201 
paired serum samples between January 2010 and December 2012 are summarised in Table 1. 202 
Twenty one counties were affected in England, Wales and Scotland with multiple outbreaks 203 
in some areas. In addition to samples submitted from the UK, 17 virus isolates obtained 204 
between 2010 and 2012 were received from the Gluck Equine Research Center, OIE 205 
reference laboratory for equine influenza in the USA (supplementary data). Outbreaks in the 206 
USA were reported from 6 states in 2010, 10 states in 2011 and 17 in 2012, many of which 207 
were described by Pusterla et al. (2011) and subsequent work by that group. During 2011 and 208 
2012, there were also outbreaks of equine influenza reported in Germany, including cases in 209 
vaccinated animals. One isolate from 2012 was submitted to the AHT by the OIE reference 210 
laboratory for Germany, for antigenic characterisation. Three virus isolates were also 211 
submitted from the Central Veterinary Laboratories, Dubai, following an outbreak in a 212 
quarantine facility. The source of infection was a group of endurance horses transported from 213 
Uruguay to Dubai, consistent with reports to the OIE of extensive outbreaks of equine 214 
influenza affecting around 2,500 horses in Uruguay during 2012. The endurance horses had 215 
UHFHLYHG D SULPDU\ FRXUVH RI WZR GRVHV RI YDFFLQH DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V216 
recommendations. 217 
Genetic analyses - HA 218 
HA1 sequences were obtained from all virus isolates, plus one swab sample from which virus 219 
could not be isolated (East Renfrewshire/1/11). For most isolates, sequence was also 220 
determined directly from the nasal swab extract. In all instances, the HA1 nucleotide 221 
 12 
 
sequence obtained from both egg isolate and swab extract was identical, suggesting that no 222 
significant selection had occurred during egg passage. Phylogenetic analysis was carried out 223 
for the recent isolates against a panel of 130 equine H3N8 HA1 nucleotide sequences from 224 
GenBank. The resulting analysis grouped the viruses into 5 well-defined clusters, 225 
corresponding to the Pre-divergent, Eurasian, American and Florida clade 1 and 2 226 
sublineages (Figure 1). These clusters were each supported by high bootstrap values, ranging 227 
from 97 to 100 after 100 replicates. All viruses isolated in the UK between 2010 and 2012 228 
belonged to the Florida clade 2 sublineage, all those characterised from the USA were of the 229 
Florida clade 1 sublineage. The strains from Dubai were most similar to clade 1 isolates from 230 
Kentucky 2011. Derived amino acid sequences were aligned against the current OIE 231 
recommended strain for Florida clade 2 (A/equine/Richmond/1/07), shown in Figure 2. In the 232 
alignment, each strain is representative of multiple isolates with identical HA1 sequences. 233 
The Florida clade 2 viruses appeared to have 3 consistent amino acid substitutions compared 234 
to Richmond/1/07, two of which were P103L and V112I (Figure 2). A further substitution, 235 
E291D, was observed between Richmond/1/07 and all of the other strains described here; this 236 
was shared by all the clade 2 viruses isolated in the UK during 2007 (Bryant et al, 2009). 237 
Two different sub-populations were isolated in the UK during the period studied here, those 238 
with an additional change at position 144 and those with a substitution at 179, which was also 239 
observed in recent isolates from France and Germany. Amongst the American clade 1 240 
viruses, three amino acid substitutions were unique to 2010 isolates from California: D31N, 241 
T163I and I230V. There were 5 consistent amino acid changes between the current clade 1 242 
OIE-recommended strain (South Africa/4/03) and isolates from 2009 onwards: G7D, R62K, 243 
D104N, A138S and V223I. The HA2 sequence for some of the isolates was also determined 244 
which revealed amino acid substitutions between the recommended vaccine strains and the 245 
most recent Florida clade 1 and 2 viruses (data not shown). These substitutions in HA2 246 
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included N169S and L187M between Richmond/1/07 and clade 2 isolates, and I198V 247 
between South Africa/4/03 and the clade 1 isolates. There were five amino acid substitutions 248 
in HA2 between the most recent clade 2 and clade 1 isolates (T43A, E50G, N169S, L187M 249 
and I198V). 250 
The conserved amino acid substitutions between the Florida clade 1 and Florida clade 2 251 
viruses were mapped to the structure of the trimeric HA molecule, using A/duck/Ukraine/68 252 
[H3N8] PDB 1MQL (Ha et al, 2003), shown in Figure 3. Four differences mapped to the top 253 
of the molecule, close to the receptor binding site, with a further 12 mapping on the surface 254 
of the molecule. For comparison, the differences between the clade 2 viruses and the OIE 255 
recommended strain Richmond/1/07 and the clade 1 viruses and the recommended strain 256 
South Africa/4/03 are also shown. The clade 1 versus clade 2 comparison shows multiple 257 
differences between strains, whereas the OIE-recommended strain for each clade shows only 258 
one or two differences on the top of the HA molecule.  259 
Genetic analyses ± NA 260 
To investigate the level of variation in NA amongst circulating strains, the nucleotide 261 
sequence of segment 6 was determined for 19 strains isolated between 2010 and 2012 from 262 
the UK, USA, Germany and Dubai, as well as representative clade 1 and 2 isolates from 2007 263 
and 2009. Phylogenetic analyses were carried out as described for HA, using a panel of 99 264 
sequences from Genbank from 1963 to 2011 (Figure 4). The topology of the NA tree was 265 
similar to that of HA and separation of viruses belonging to Florida clades 1 and 2 was well-266 
supported with a bootstrap value of 98%. Major clades also correlated with significant 267 
country-wide outbreaks in 1979, 1989, 2003 and 2007. Three recent Florida clade 1 isolates, 268 
(Dorset/09, Lanarkshire/09 and Yorkshire/3/09) had an NA segment that was more similar to 269 
those of the clade 2 viruses and one Florida clade 2 isolate (Perthshire/1/09) had an NA more 270 
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similar to those of clade 1 viruses, indicating that reassortment had taken place between clade 271 
1 and clade 2. These isolates are highlighted in Figure 4.  272 
 273 
Derived amino acid sequences were aligned against representative strains from four major 274 
clades identified by phylogenetic analysis and are shown in Figure 5. Multiple amino acid 275 
substitutions were observed between sublineages with signature substitutions readily 276 
identified for the current Florida clade 1 and clade 2 viruses compared with the older 277 
American strains. There were 16 amino acid substitutions between the most recent UK 278 
isolates from clade 1 and clade 2. The majority of changes occurred within the first 80 279 
residues, including the membrane anchor sequence and stalk region of NA; these are not 280 
included in the protein structure solved for various subtypes of NA. For the purpose of 281 
structure mapping, the amino acid numbering of the predicted ectodomain was adjusted to 282 
correspond to that present in the H5N1 and H3N8 NA protein structure database files 2HTY 283 
and 2HT5. Multiple changes occurred on the surface of NA, shown mapped on the tetrameric 284 
structure of H5N1 (Figure 6), affecting both the distal and proximal surfaces of the molecule. 285 
An additional substitution V147I within the 150 loop was observed in equine viruses from 286 
the Japanese and Australian outbreak in 2007.  287 
Antigenic characterisation 288 
Low passage virus isolates were characterised by HI assay using post infection ferret antisera 289 
raised against eight representative EIV strains and the homologous reference strains. Sera 290 
included those raised against representatives from relevant sublineages [American 291 
(Kentucky), Florida clade 1, Florida clade 2], current UK vaccine strains and OIE 292 
recommended strains, as indicated in Table 2. All virus isolates raised low titres against the 293 
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European sera (data not shown), as expected from their genetic characterisation.  Ferret 294 
antisera against the American Kentucky lineage vaccine strains Newmarket/1/93 and 295 
Kentucky/98 recognised the Florida clade 2 isolates from 2010 to 2012, but gave a slightly 296 
lower titre than against homologous strains. They typically showed a 2-fold difference for 297 
Kentucky/98 and 2- to 4-fold lower titre for Newmarket/1/93. These sera recognised the 298 
Florida clade 1 viruses poorly, with most strains showing a 16- to 64- fold reduction against 299 
Newmarket/1/93 and an 8- to 16-fold lower titre against Kentucky/98 compared to 300 
homologous antigen. Ferret antisera were raised against the early representative of the Florida 301 
clade 2 viruses, Kentucky/97, which has sequence similarity to the older American strains, 302 
and outbreak strains Newmarket/5/03 and Richmond/1/07 (the current OIE-recommended 303 
clade 2 strain). These sera all recognised the clade 2 isolates from 2010 to 2012 and in most 304 
instances, to at least the same level as their respective homologous strains. None of the sera 305 
raised the maximum titre against their homologous strains; this was particularly noticeable 306 
for Kentucky/97 (Table 2).  Most of the clade 2 field isolates gave a 2- to 4-fold higher titre 307 
than Kentucky/97. All three of the antisera raised to clade 2 viruses gave lower titres against 308 
the clade 1 isolates from 2010 to 2012 than the clade 2 strains, reflecting the genetic 309 
differences between the two groups. Three sera were raised against clade 1 strains, including 310 
South Africa/4/03, one of the current OIE recommended strains for vaccines. The reciprocal 311 
pattern was seen with these sera, all sera recognised the clade 1 field isolates with high titres 312 
but with lower titres against the clade 2 strains. In both directions, 8- to 16-fold differences in 313 
titre were common suggesting antigenic divergence between the two clades.  314 
Antigenic cartography 315 
The antigenic relationships between 44 equine influenza A(H3N8) viruses, including the 316 
recent isolates described above and a reference panel of representative Florida clade 1 and 317 
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clade 2 strains are shown in Figure 7. The viruses grouped into two distinct antigenic clusters, 318 
with all the Florida clade 2 isolates falling into the blue cluster and all the clade 1 isolates 319 
grouping together in the red cluster. This is consistent with our previous findings, showing 320 
that the two phylogenetic clades were antigenically distinct (Lewis et al, 2011). The current 321 
recommended vaccine strains, A/equine/Richmond/1/07 and A/equine/South Africa/4/03, for 322 
either clade were located within their respective clusters and the antigenic distance between 323 
each isolate and the representative strain did not exceed 2.1 antigenic units, equivalent to a 4-324 
fold difference in HI titre. When we measured the antigenic distances from ferret sera raised 325 
to current and previous OIE-recommended strains for the Clade 2 cluster, we found that on 326 
average, currently circulating strains were 1.5 antigenic units from the 327 
A/equine/Richmond/1/2007 serum, but on average 2 antigenic units from a previously 328 
recommended vaccine strain, A/equine/Newmarket/1/1993 serum. 329 
 330 
HI of strains against Richmond and South Africa equine sera 331 
To determine whether the antigenic differences between strains belonging to the American, 332 
Florida clade 1 and Florida clade 2 sublineages could be distinguished by equine sera, HI 333 
assays were carried out against a panel of post-infection equine sera for a representative 334 
selection of strains from the three groups (Table 3). Compared with ferret sera, the titres were 335 
lower for equine sera, with homologous titres only reaching 128 rather than up to 1024. The 336 
two American sera showed lower titres against viruses from both of the Florida sublineages 337 
than the American strains; the antiserum raised against the older strain Kentucky/91 raised 338 
even lower titres than Kentucky/99. Although differences were subtle, these sera appeared to 339 
recognise the clade 1 strains better than clade 2, in contrast to ferret sera raised against 340 
similar strains (Table 2).  341 
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Of the sera raised against more recent viruses, both sera from Richmond/1/07-infected ponies 342 
recognised all three groups of viruses, with no more than a 2-fold difference in titre between 343 
field isolates and Richmond/1/07. The results for the South Africa clade 1 sera were slightly 344 
different, with the highest titres raised against homologous or very closely related clade 1 345 
viruses. Differences in HI titre within this group of viruses were less than 2-fold compared 346 
with the homologous titre for South Africa/4/03. However, the clade 1 sera consistently 347 
raised lower HI titres against both American and clade 2 viruses, giving differences of 2- to 348 
4-fold compared with the South Africa/4/03 strain. 349 
 350 
351 
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Discussion 352 
Equine influenza viruses belonging to the H3N8 subtype are thought to have crossed the 353 
species barrier from birds in the early 1960s and subsequently spread worldwide. They have 354 
continued to circulate since then, causing widespread outbreaks in naïve populations, such as 355 
South Africa in 2003 and Australia in 2007, but also occasionally in vaccinated horses. 356 
Extensive outbreaks in Europe in highly vaccinated horses in the late 1980s demonstrated 357 
that circulating equine influenza viruses had undergone significant antigenic drift from the 358 
strains included in vaccines and highlighted the need for effective surveillance programmes.  359 
In 2003, two large scale epidemics of equine influenza in the UK and South Africa led to the 360 
division of the Florida sublineage of equine influenza into two clades, 1 and 2. The original 361 
difference was based upon two amino acid substitutions within HA1 at positions 78 and 159, 362 
which were sufficient to cause an antigenic difference that was recognisable by ferret sera 363 
(OIE, 2008). Since then, the two clades have diverged further and we show here that there are 364 
now 9 consistent amino acid differences between viruses from the different groups isolated in 365 
2012 with a further 2 substitutions between subsets of the clade 2 viruses. Additional variants 366 
arose during this period as a result of reassortment between clade 1 and clade 2 viruses, 367 
which led to new combinations of HA and NA.  368 
In 2010, the OIE recommended that vaccine manufacturers should include a representative of 369 
both Florida clade 1 and Florida clade 2 viruses (OIE 2010). Surveillance data reported here 370 
confirm that viruses from both clades continued to circulate, with viruses of Florida clade 1 371 
likely to be the cause of multiple large-scale outbreaks in South America. Clade 2 viruses 372 
predominated in Europe, causing outbreaks in the UK, France, Ireland and Germany. 373 
Surveillance data therefore support inclusion of both clades in vaccines for horses that travel 374 
between continents.  375 
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Antigenic characterisation of the strains reported here indicated that representatives of the 376 
Florida clades 1 and 2 could be distinguished from each other readily, with differences 377 
ranging between 2- and 16-fold by HI. These results were comparable to those seen with 378 
viruses isolated in 2009 (Bryant et al., 2011), suggesting that the ferret model does not 379 
distinguish between viruses with HA1 molecules containing the most recent amino acid 380 
differences. These substitutions were primarily conservative changes, the notable exception 381 
being the P103L substitution seen in recent clade 2 viruses. However, this position is buried 382 
within the HA molecule and is not likely to affect the binding of ferret antisera. Similarly, 383 
ferret sera raised against Kentucky lineage vaccine strains from the 1990s continued to 384 
recognise Florida clade 2 viruses. However, there was typically a difference of 4-fold 385 
between the titres against the most recent clade 2 viruses from 2011 and 2012 compared with 386 
the homologous American reference strains Newmarket/1/93 and Kentucky/98, whereas 387 
some of those from 2010 showed only a 2-fold difference. Caution should be observed in 388 
interpretation of cross-reactive titres, as ferret sera to Newmarket/1/93 vaccine strain cross-389 
reacted well against the Newmarket/5/03 outbreak strain from the 2003 epidemic in the UK, 390 
however commercial vaccines containing this strain failed to protect against the outbreak 391 
strain (Newton et al., 2006). Cross-reaction was therefore a poor indicator of cross protection 392 
in this instance. Clade 1 ferret sera cross-reacted well against other members of the group and 393 
also recognised clade 2 viruses, but to a lower level.  Interestingly, equine sera raised against 394 
Richmond/1/07 reacted well against viruses belonging to all 3 sublineages whereas South 395 
Africa/4/03 did not react as well against the clade 2 viruses. This result suggests that 396 
Richmond/1/07 could make a good vaccine strain for protecting against both clade 1 and 397 
clade 2 viruses, with the caveat outlined above that cross-reaction does not necessarily 398 
correlate with cross-protection. Ideally, equine sera would be used for antigenic 399 
characterisation of equine influenza virus strains, however these sera are often broadly cross-400 
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reactive making them insensitive to antigenic differences between strains. In our experience, 401 
the HI titres are often low and strains that give a 4- or 8-fold difference with ferret sera may 402 
only raise a 2-fold difference using equine sera, making interpretation difficult. 403 
To date, vaccine strain selection for EIV has focussed solely on HA genetic and antigenic 404 
differences and there is a lack of sequence data available for NA for recent isolates from 405 
Florida clade 2. Comparison of amino acid sequences shown here indicated that NA had 406 
undergone considerable divergence since 1963 and outbreak strains from 1979, 1989, 2003 407 
and 2007 had multiple amino acid changes compared with previous sublineages. Recent 408 
Florida clade 1 and clade 2 viruses differed by 16 or more amino acids and it was clear that 409 
reassortment had taken place in strains isolated in the UK. Multiple changes occurred within 410 
the stalk region of NA and so could not be mapped on the structure of the tetrameric head 411 
region of the NA; however changes also occurred on both the upper and lower surfaces of the 412 
head region, including regions close to the active site and within the C-terminal region where 413 
human sera have been shown to recognise epitopes in the NA of H5N1 viruses (Khurana et 414 
al., 2011). Also of interest was the V147I substitution observed in isolates from the 2007 415 
outbreaks in Japan and Australia. All other H3N8 viruses of avian or equine origin, with NA 416 
sequences currently available on Genbank, had valine at this position. The exceptions were 417 
the H3N8 canine isolates from the USA, which had isoleucine (data not shown). This 418 
position is equivalent to V149 of the N1 structure and falls within the 150 loop of NA 419 
(Russell et al, 2006), an important region for NA activity (Lin et al. 2010). The conformation 420 
of this loop may affect the size of the adjacent 150 cavity, which potentially differs between 421 
group 1 and group 2 NAs.  422 
Further work is required to determine the role of antibodies to NA in immunity in the horse 423 
but they may contribute to vaccine efficiency and immune selection (Johansson et al., 1998).  424 
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 425 
Conclusion 426 
Equine influenza Florida sublineage clade 1 and 2 viruses continued to cause 427 
outbreaks worldwide between 2010 and 2012. Clade 2 predominated in Europe while clade 1 428 
was isolated in North and South America. Sequence analysis of NA revealed that 429 
reassortment had occurred between the two clades and some virus isolates from 2009 had 430 
new combinations of HA and NA. The two sublineages have diverged further since 2009 and 431 
can be distinguished readily by antigenic analysis. Current OIE vaccine strain 432 
recommendations for representatives of Florida clade 1 and clade 2 remain adequate, based 433 
on antigenic differences determined by HI. 434 
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Tables  572 
Table 1. Outbreaks of EIV in the UK 2010 to 2012. 573 
Footnote: NP ELISA ± nucleoprotein enzyme linked immunosorbent assay, qPCR ± 574 
quantitative polymerase chain reaction, HI ± haemagglutination inhibition assay, HA Acc. ± 575 
Haemagglutinin  accession numbers, NA Acc. ± Neuraminidase accession numbers. 576 
 577 
Table 2. HI titres of EIV strains using ferret sera.  578 
Footnote: The lineage of new isolates is indicated on the left and ordered by isolation 579 
date. Homologous titres are shown in bold, titres for sera against strains from the same 580 
sublineage are highlighted in grey boxes. New/1/93 ± A/eq/Newmarket/1/93, Ken/97 ± 581 
A/eq/Kentucky/97,      Ken/98 ± A/eq/Kentucky/98, New/5/03 ± A/eq/Newmarket/5/03, 582 
SA/4/03 ± A/eq/South Africa/4/03, Rich/1/07 ± A/eq/Richmond/1/07, Lin/1/07 ± 583 
A/eq/Lincolnshire/1/07, Dor/09 ± A/eq/Dorset/09. Am ± American lineage, FC1 ± Florida 584 
sublineage clade 1, FC2 - Florida sublineage clade 2. 585 
 586 
Table 3. HI titres of EIV strains using post-infection equine sera. 587 
Footnote: The lineage of strains tested is indicated on the left. Titres for sera against 588 
strains from the same sublineage are highlighted in grey boxes, homologous titres are shown 589 
in bold. Ken/91 ± A/eq/Kentucky/91, Ken/99 - A/eq/Kentucky/99, Rich/07 - 590 
A/eq/Richmond/1/07, Ken/4/07 ± A/eq/Kentucky/4/07, SA/4/03 ± A/eq/South Africa/4/03. 591 
For Rich/07 and SA/4/03 antisera, numbers 1 and 2 relate to serum samples from pony 1 and 592 
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pony 2 respectively. Am ± American lineage, FC1 ± Florida sublineage clade 1, FC2 - 593 
Florida sublineage clade 2. 594 
 595 
Supplementary data 596 
Table S1 Virus isolates from outside the UK: Genbank accession numbers. FC1 ± Florida 597 
sublineage clade 1, FC2 - Florida sublineage clade 2. 598 
599 
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Figure captions 600 
Figure 1  601 
HA Phylogenetic Tree 602 
Phylogenetic analysis of HA1 nucleotide sequences encoded by EIV. A maximum likelihood 603 
tree was created using PhyML version 3. Bootstrap values obtained after 100 replicates are 604 
shown at major nodes. Amino acid substitutions are indicated at branch points, or in brackets. 605 
Phylogenetic groups are shown by continuous bars on the right, as indicated. Accession 606 
numbers for the sequences reported in this manuscript are listed in Table 1. Sequences are 607 
coloured by date of isolation for the years 2010 (green), 2011 (red) and 2012 (blue) with the 608 
older isolates in black. Representative OIE-recommended vaccine strains 609 
A/eq/Richmond/1/07 and A/eq/South Africa/4/03 are shown in bold. Reassortant strains 610 
containing HA from one Florida clade and NA from the other, identified in this manuscript, 611 
are highlighted in yellow. 612 
Figure 2 613 
Alignment of HA1 amino acid sequences. 614 
Derived amino acid differences in HA1 observed between representative field strains from 615 
Florida clade 2 and clade 1 isolated during 2010-2012 compared to A/eq/Richmond/1/07 616 
(top). The sublineage of isolates is indicated on the left and ordered by isolation date. 617 
Residues are numbered from 1 to 329 starting with the serine residue downstream of the 618 
predicted signal peptide. Amino acid identity to A/eq/Richmond/1/07 is shown with a dot. 619 
Examples of strains from 2009 are included to allow comparison with Bryant et al (2011). 620 
 621 
Figure 3 622 
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HA structures. 623 
Location of the amino acid differences on the A/duck/Ukraine/1/63 H3 HA structure (Ha et 624 
al, 2003) between OIE recommended Florida clade 1 strain A/eq/South Africa/4/03 and 625 
2010-2012 clade 1 isolates, OIE recommended Florida clade 2 strain A/eq/Richmond/1/07 626 
and 2010-2012 clade 2 isolates and 2010-2012 isolates from Florida clade 1 and clade 2. 627 
Established changes are shown in red, those that appeared in one year only are shown in blue. 628 
HA1 residues 112, 179, 230 and 251 are buried. HA1 residue 7 and HA2 residues 187 and 629 
198 are not shown. 630 
Figure 4 631 
NA Phylogenetic Tree 632 
Phylogenetic analysis of NA nucleotide sequences encoded by EIV. A maximum likelihood 633 
tree was created using PhyML version 3. Bootstrap values obtained after 100 replicates are 634 
shown at major nodes. Amino acid substitutions are indicated at branch points, or in brackets. 635 
Phylogenetic groups are shown by continuous bars on the right, as indicated. Accession 636 
numbers for the sequences reported in this manuscript are listed in Table 1. Sequences are 637 
coloured by date of isolation for the years 2010 (green), 2011 (red) and 2012 (blue) with the 638 
older isolates in black. Representative OIE-recommended vaccine strains 639 
A/eq/Richmond/1/07 and A/eq/Ohio/03 (A/eq/South Africa/4/03-like) are shown in bold. 640 
Reassortant strains containing NA from one Florida clade and HA from the other, identified 641 
in this manuscript, are highlighted in yellow. 642 
Figure 5 643 
Alignment of NA amino acid sequences. 644 
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Derived amino acid differences in NA observed between representative strains from Pre-645 
divergent, American, Eurasian, Florida clade 1 and Florida clade 2 sublineages compared to 646 
A/eq/Miami/63 (top). The sublineage of isolates is indicated on the left and ordered by 647 
isolation date. Residues are numbered from 1 to 470 starting with the methionine residue at 648 
the start of the predicted signal peptide. The numbering has not been adjusted to correspond 649 
to N1 or N2 numbering. Amino acid identity to A/eq/Miami/63 is shown with a dot.  650 
 651 
Figure 6 652 
NA structure 653 
Location of the amino acid differences on the H5N1 NA structure (Russell et al., 2006) 654 
between OIE recommended Florida clade 2 strain A/eq/Richmond/1/07 and 2010-2012 clade 655 
2 isolates, OIE recommended Florida clade 1 strain A/eq/South Africa/4/03 and 2010-2012 656 
clade 1 isolates, as well as 2010-2012 isolates from Florida clade 1 and clade 2. Established 657 
changes are shown in red, those that appeared in one year only are shown in blue. 658 
Figure 7 659 
Antigenic cartography 660 
Antigenic map showing the relationships between virus strains isolated between 2010 and 661 
2012. Virus strains are shown as spheres, the positions of sera are shown as open boxes. The 662 
OIE-recommended vaccine strains are indicated in black (A/eq/South Africa/4/2003 & 663 
A/eq/Richmond/1/2007) and their corresponding sera as larger squares; representative strains 664 
from clade 1 (A/eq/Lincolnshire/1/2007, A/eq/Dorset/2009),  clade 2 (A/eq/Kentucky/1997, 665 
A/eq/Newmarket/5/2003) and current commercial vaccine strains(A/eq/Newmarket/1/1993, 666 
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A/eq/Kentucky/1998) are highlighted in turquoise. The scale bar indicates one antigenic unit, 667 
equivalent to a 2-fold difference in HI titre. 668 
Date Location
Detection 
method
Premises VI Virus Name HA acc. NA acc.
May-10 Lincolnshire NP ELISA Sanctuary, 150+ affected 5 A/eq/Lincolnshire/1/10 KF026381 -
May-10 Shropshire NP ELISA Private yard, all of 4 affected 1 A/eq/Shropshire/10 KF026378 KF049195
Jun-10 Surrey NP ELISA Riding school, 10 affected out of 30 3 A/eq/Surrey/2/10
A/eq/Surrey/4/10
KF026376
KF026377
-
-
Jul-10 Nottinghamshire NP ELISA Small private yard, 1 affected 1 A/eq/Nottinghamshire/1/10 KF026379 -
Aug-10 Worcestershire NP ELISA Private yard 1 A/eq/Worcestershire/1/10 KF026375 -
Aug-10 Nottinghamshire HI Private yard, 5 affected - - - -
Aug-10 Lanarkshire NP ELISA Livery/riding stables, 1 affected and
isolated, 30 unaffected
1 A/eq/Lanarkshire/1/10 KF026380 -
-
Sep-10 Hampshire NP ELISA Unknown, 2 out of 2 ponies affected 2 A/eq/Hampshire/1/10
A/eq/Hampshire/2/10
KF026382
KF026383
-
-
Sep-10 Cumbria NP ELISA Private yard, 1 horse affected for 10 days
before sampling, other horses unaffected
- - - -
Nov-10 Leicestershire NP ELISA Unknown, weak positive 0 - - -
Jun-11 Cardiff NP ELISA 1 affected 0 - - -
Aug-11 Wiltshire HI 1 affected - - - -
Aug-11 Lanarkshire NP ELISA Private yard, 1 affected 1 A/eq/Lanarkshire/1/11 KF026385 -
Aug-11 Surrey NP ELISA Livery yard, 2 affected 1 A/eq/Surrey/1/11 KF026384 -
Sep-11 Lanarkshire NP ELISA Private yard, 1 affected 1 A/eq/Lanarkshire/2/11 KF026386 -
Oct-11 Kent NP ELISA Eventing yard, 2 affected 1 A/eq/Kent/1/11 KF026387 -
Oct-11 Devon NP ELISA Sanctuary, 2+ affected 2 A/eq/Devon/1/11
A/eq/Devon/2/11
KF026389
KF026390
KF049194
-
Nov-11 Berkshire HI Hunt yard, 2 affected - - - -
Nov-11 East Renfrewshire NP ELISA Livery yard, 3 affected 1
-
A/eq/East Renfrewshire/2/11
A/eq/East Renfrewshire/1/11
KF026388
KF049198
KF049172
-
Dec-11 Cheshire NP ELISA Training yard, 3 affected 1 A/eq/Cheshire/1/11 KF026391 -
Apr-12 Lancashire qPCR Training yard, weak positive, 3 affected 0 - - -
Sep-12 Essex qPCR Private yard, weak positive, 3 affected 0 - - -
Oct-12 County Durham qPCR Livery yard, weak positive, 3 affected 0 - - -
Nov-12 Roxburghshire qPCR 3 affected 1 A/eq/Roxburghshire/1/12 KF026395 KF049190
Nov-12 County Durham qPCR Private yard, 6 affected 2 A/eq/County Durham/2/12 KF026396 KF049192
Nov-12 Worcestershire qPCR Riding centre, 10 affected 2 A/eq/Worcestershire/1/12
A/eq/Worcestershire/2/12
KF026375
KF026392
KF049174
KF049188
Nov-12 Herefordshire qPCR Private yard, 2 affected 0 - - -
Nov-12 Wiltshire HI Riding school, 12 affected - - - -
Nov-12 Worcestershire qPCR Livery yard, 2 affected 2 A/eq/Worcestershire/3/12
A/eq/Worcestershire/4/12
KF026393
KF026394
-
KF049189
Table 1
REFERENCE FERRET ANTISERA
REFERENCE STRAINS
Newmarket/1/93
Kentucky/98
Kentucky/97
Newmarket/5/03
Richmond/1/07
South Africa/4/03
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Dorset/09
FLORIDA CLADE 2
Perthshire/1/09
Yorkshire/09
Lincolnshire/1/10
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Surrey/2/10
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Hampshire/2/10
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Cheshire/1/11
Roxburghshire/12
Co. Durham/2/12
Co. Durham/3/12
Worcestershire/1/12
Worcestershire/2/12
Worcestershire/3/12
Worcestershire/4/12
Lichtenfeld/1/12
FLORIDA CLADE 1
California/2/10
Oregon/1/10
Kentucky/1/11
New York/1/11
Pennsylvania/2/11
Pennsylvania/3/11
Pennsylvania/5/11
Pennsylvania/6/11
Dubai/1/12
Kentucky/1/12
Kentucky/2/12
Kentucky/3/12
Kentucky/5/12
Texas/1/12
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12864512
181
128
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32 64
181
128256 1024
128
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128 64 128 128 64
256128 128 181 181
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128
256
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64
128
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512128
128 256128
128
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128
128
128
128
32
128
64
64
64
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32
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512
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32
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23
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362 256 512
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8
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8
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16
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32
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<8
16
16
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8
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64 64 64
128 128 128 1024
128 128
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1024 724
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512 512
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512
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Table 2
Ken/91 Ken/99 Rich/07 1 Rich/07 2 Ken/4/07 SA/4/03 1 SA/4/03 2
Am Am FC2 FC2 FC1 FC1 FC1
REFERENCE STRAINS
AMERICAN
Newmarket/1/93 64 64 256 256 91 64 64
Kentucky/98 128 128 256 256 128 64 45
FLORIDA CLADE 2
Kentucky/97 16 64 128 128 91 64 64
Newmarket/5/03 45 91 181 181 91 45 64
Richmond/1/07 <8 32 128 128 45 32 32
Shropshire/10 32 91 256 256 128 64 64
FLORIDA CLADE 1
South Africa/4/03 45 91 128 181 128 128 128
Lincolnshire/1/07 91 91 256 256 128 91 128
Dorset/09 45 91 256 256 128 91 181
REFERENCE EQUINE ANTISERA
Table 3
Miami/63
Fontainebleau/79
Newmarket/79
Kentucky/2/81
Sussex/89
Yvelines/89
Switzerland/07
Rome/5/91 (189E)
Newmarket/2/93
Hong Kong/92
Lambourn/92
Grosbois/98
Leicester/2/00
Lincolnshire/1/02 (48I)
Benelux/15/03
Aboyne/05 (163T)
Kentucky/1/92
Kentucky/1/91
Kildare/92
Argentina/225/95
Argentina/352/96
La Plata/93
Argentina/1/93
Argentina/1/94
Alaska/1/91
Kentucky/1/94
Cheshire/2/06
Lambourn/93
Newmarket/1/93
Kentucky/1/96 (Q190K)
Kentucky/1/98
Oklahoma/00
Kentucky/9/95 (Q190K)
Argentina/1/99 (Q190E, E193K)
Lonquen/1/06 (Q190K)
Florida/1/93
Florida/1/94
Kentucky/1/97
New York/1/99
Kentucky/5/02
Kentucky/4/04
Stoke-on-Trent/04
Newmarket/5/03
Sweden/04
Wales/2/04
Wales/05
Lincolnshire/06
Essex/1/05
Lanark/1/05
Southampton/1/06
Lanark/06
Cheshire/3/07
Northumberland/1/08
Newmarket/07
Perthshire/1/09
Yorkshire/3/09
Spain/1/09
Worcestershire/08
Lothian/08
Lanarkshire/1/08
Richmond/2/07
RICHMOND/1/07
Southampton/1/07
Cheshire/2/07
Aboyne/2/08
Aboyne/1/08
Nissan-Lez-Enserune/1/10
Aureilhan/2/10
La Baule/1/10
Hawick/1/08
Wildeshausen/1/08
Leicestershire/08
Mongolia/1/08
Liaoning/9/08
Xinjiang/5/07
Inner Mongolia/8/08
Heilongjiang/1/10
Heilongjiang/10/08
Mongolia/20/11
Mongolia/56/11
Heilongjiang/1/11
Mongolia/6/11
Mongolia/3/11
Bokel/1/11
Ittlingen/1/11
East Renfrewshire/2/11
Lichtenfeld/1/12 (L103P)
Yokohama/AQ13/10
Viersen/10
Hamburg/10
Waldalgesheim/10
Hampshire/1/10
Shropshire/10
Marcy-lEtoile/1/10
Nottinghamshire/10
Worcestershire/1/10
Lanarkshire/1/10
Lincolnshire/1/10
Eyragues/1/10
Lanarkshire/2/11
Kent/1/11
Surrey/1/11
Cheshire/1/11
Devon/1/11
Worcestershire/4/12
Roxburghshire/1/12
County Durham/2/12
Worcestershire/2/12
Worcestershire/3/12
SOUTH AFRICA/4/03
Ohio/1/03
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Nottinghamshire/09
Oregon/1/10
California/2/10
Pennsylvania/6-15/11
Pennsylvania/3-7/11
Pennsylvania/2-5/11
Pennsylvania/5-5/11
Yokohama/AQ29/11
Yokohama/AQ5/11
Yokohama/AQ79/11
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Richmond/1/07            SQNPISNNNT ATLCLGHHAV ANGTLVKTIS DDQIEVTNAT ELVQSISMGK ICNNSYRILD GRNCTLIDAM LGDPHCDVFQ YENWDLFIER SSAFSNCYPY DIPDYASLRS  
Perthshire/1/09          .......... .......... .......... .......... .......... .......... .......... .......... .G........ .......... ..........  
Yorkshire/3/09           .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  
Shropshire/10            .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..L.......  
Surrey/4/10              .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..L.......  
Nottinghamshire/10       .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..L....F..  
Devon/1/11               .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..L.......  
East Renfrewshire/2/11   .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..L.......  
Lichtenfeld/1/12         .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  
Clade 1 
South Africa/4/03        ......G... .......... .......... .......... .......... .......... .......... .......A.. .......... .......... ..........  
Dorset/09                ......D... .......... .......... .......... ....G..... .......... .K........ .......A.. .......... .......... ...N......  
Kentucky/09              ......D... .......... .......... .......... .......... .......... .K........ .......A.. .......... .......... ...N......  
California/2/10          ......D... .......... .......... N......... .......... .......... .K........ .......A.. .......... .......... ...N......  
Oregon/1/10              ......D... .......... .......... .......... .......... .......... .K........ .......A.. .......... .......... ...N......  
Pennsylvania/1-2/11      ......D... .......... .......... .......... .......... .......... .K........ .......A.. .......... .......... ...N......  
Kentucky/2/12            ......D... .......... .......... .......... .......... .......... .K........ .......A.. .......... .......... ...N......  
Texas/1/12               ..T...D... .......... .......... .......... .......... .......... .K........ .......A.. .......... .......... ...N......  
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Clade 2 
Richmond/1/07            IVASSGTLEF TAEGFTWTGV TQNGRSGACK RGSADSFFSR LNWLTKSGNS YPTLNVTMPN NKNFDKLYIW GIHHPSSNQE QTKLYIQESG RVTVSTKRSQ QTIIPNIGSR  
Perthshire/1/09          .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  
Yorkshire/3/09           .......... .......... .......... .......... .......... .......... .......... .......... .......... ........N. ..........  
Shropshire/10            .I........ .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  
Surrey/4/10              .I........ .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  
Nottinghamshire/10       .I........ .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  
Devon/1/11               .I........ .......... .......... ...V...... .......... .......... .......... .......... .......... .......... ..........  
East Renfrewshire/2/11   .I........ .......... .......... .......... .......... .......... ........V. .......... .......... .......... ..........  
Lichtenfeld/1/12         .I........ .......... .......... .......... .......... .......... ........V. .......... .......... .......... ..........  
Clade 1 
South Africa/4/03        .......... .......... .......... .......... ........S. .......... .......... .......... .......... .......... ..........  
Dorset/09                .......... .......... .......S.. .......... ........S. .......... .......... .......... .......... .......... ..........  
Kentucky/09              .......... .......... .......S.. .......... ........S. .......... .......... .......... .......... .......... ..........  
California/2/10          .......... .......... .......S.. .......... ........S. ..I....... .......... .......... .......... .......... ..........  
Oregon/1/10              .......... .......... .......S.. .......... ........S. .......... ....N..... .......... .......... .......... ..........  
Pennsylvania/1-2/11      .......... .......... .......S.. .......... ........S. .......... .......... .......... .......... .......... ..........  
Kentucky/2/12            .......... .......... .......S.. .......... ........S. .......... .......... .......T.. .......... .......... ..........  
Texas/1/12               .......... .......... .......S.. .......... ........S. .......... .......... .......... .......... .......... ..........  
 
 
                         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|.... 
                                 230        240        250        260        270        280        290        300        310        320                           
Clade 2 
Richmond/1/07            PWVRGQSGRI SIYWTIVKPG DILMINSNGN LVAPRGYFKL KTGKSSVMRS DVPIDICVSE CITPNGSISN EKPFQNVNKV TYGKCPKYIR QNTLKLATGM RNVPEKQIR 
Perthshire/1/09          .......... .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
Yorkshire/3/09           .......... .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
Shropshire/10            .......... .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
Surrey/4/10              ..I....... .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
Nottinghamshire/10       .......... .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
Devon/1/11               .......... .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
East Renfrewshire/2/11   .......... .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
Lichtenfeld/1/12         .......... .M........ .......... .......... .......... .......... .......... D......... .......... .......... ......... 
Clade 1 
South Africa/4/03        .......... .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
Dorset/09                ..I....... .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
Kentucky/09              ..I....... .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
California/2/10          ..I......V .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
Oregon/1/10              ..I....... .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
Pennsylvania/1-2/11      ..I....... .......... .......... F......... .......... .......... .......... D......... .......... .......... ......... 
Kentucky/2/12            ..I....... .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
Texas/1/12               ..I....... .......... .......... .......... .......... .......... .......... D......... .......... .......... ......... 
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Figure 4
  
                         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                                  10         20         30         40         50         60         70         80         90        100                            
Pre-divergent 
Miami/63                 MNPNQKIITI GSASLGLVIL NVILHVVSII VTVLVLSNNG TGPNCNGTII REYNETVRVE RITQWYNTNI IEYIEEPSNE YYMSNTEPLC EAQGFAPFSK  
Newmarket/79             ........A. ......IL.. .......... ......N... ..L....... .......... .........T .....R.... ...N...... ..........  
Fontainebleau/79         ........A. ......IL.. .......... ......N... ..L....... .......... .........T .....R.... ...N...... ..........  
Eurasian 
Sussex/89                ........A. ......IL.. .......... ......N... ..L....... .......... ........ST .....R.... ...N...... ..........  
Newmarket/2/93           ........A. ......VL.. .......... ......N... ..L....... .......... ........ST .....R.... ...N...... ..........  
Aboyne/05                ........A. ......VL.. .I........ ....F.N... .SL....... .........K K.......ST .....RS... ...N...... ..........  
Lincolnshire/06          ........A. ......VL.. .I........ ......N... .SL....... .......... K.......ST .....RS... ...N...... ..........  
American 
Newmarket/1/93           ........A. ......IL.I .......... ......N... ..L..K.... .......... ........ST .....R.... ...N...... ..........  
Kentucky/8/94            ........A. ......IL.I .......... ......N... ..L..K.... .......... ........ST .....R.... ...N...... ..........  
Clade 1 
Ohio/03                  ........A. .F....IL.I .......... ......N..R .DL..K.... .......... K.......ST .K...R.... ...N...... ..........  
Lincolnshire/07          ........A. .F....IL.I .......... ....A.N..K .DL..K.... .......... K.......SA .K...R.... ...N...... ..........  
Dubai/1/12               .......MA. .F....IL.I .......... ....A.N..R .DL..K.... .......... K.......ST .K...R.... ...N...... ..........  
Clade 2 
Newmarket/5/03           ........A. .F....IL.I .......... ......N... ..L..K.... .......... K.......SA .K...R.P.. ...N...... ..........  
Richmond/1/07            .......... ......IL.I .......... ......N..E ..L..K.... .......... K....H..SA .K...R.P.. ...N...... ..........  
East Renfrewshire/2/11   .......... ......IL.I .......... ......N..E ..L..K.... .......... K....H..SA .K...R.P.. ...N...... ..........  
Worcestershire/1/12      .......... ......IL.I ....N..... ......N..E ..L..K.... .......... K....H..SA .K...R.P.. ...N...... ..........  
 
 
                         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                                 110        120        130        140        150        160        170        180        190        200                   
Pre-divergent 
Miami/63                 DNGIRIGSRG HVFVIREPFV SCSPLECRTF FLTQGSLLND KHSNGTVKDR SPYRTLMSVE VGQSPNVYQA RFEAVAWSAT ACHDGKKWMT VGVTGPDAQA  
Newmarket/79             .......... .......... .......... ...H...... .......... .........K .......... .......... .......... .......T..  
Fontainebleau/79         .......... .......... .......... ...H...... .......... .........K .......... .......... .......... .......T..  
Eurasian 
Sussex/89                .......... .......... ....S..... .......... .......... .........K I......... ...S...... .......... .......N..  
Newmarket/2/93           .......... .......... ....S..... .......... .......... .........K I......... ...S...... .......... .......N..  
Aboyne/05                .......... .......... ....S..... .......... .......... .........K I......... ...S...... .......... .......N..  
Lincolnshire/06          .......... .......... ....S..... .......... .......... .........K I......... ...S...... .......... .......N..  
American 
Newmarket/1/93           .......... .......... ....S..... .......... .......... .........K I......... ...S...... .......... .......N..  
Kentucky/8/94            .......... .......... ....S..... .......... .......... .........K I......... ...S...... .......... .......N..  
Clade 1 
Ohio/03                  .......... .......... ....S..... .......... .......... .........K I......... ...S...... .......... .......N..  
Lincolnshire/07          .......... .......... ....S..... .......... .......... .........K I......... ...S...... .......... .......N..  
Dubai/1/12               .......... .......... ....S..... .......... .......... .........K I......... ...S...... .......... .......N..  
Clade 2 
Newmarket/5/03           .......... .......... ....S..... .......... .......... .........K I......... ...S...... .......... .......N..  
Richmond/1/07            .......... .......... ....S..... .......... .......... .........K I......... ...S...... .......... I......N..  
East Renfrewshire/2/11   ........K. .......... ....S..... .......... .......... .........K I......... ...S...... .......... I......N..  
Worcestershire/1/12      ........K. .......... ....S..... .......... .......... .........K I......... ...S...... .......... I......N..  
 
 
                         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                                 210        220        230        240        250        260        270        280        290        300                   
Pre-divergent 
Miami/63                 VAVVHYGGVP VDVINSWAGD ILRTQESSCT CIKGDCYWVM TDGPANRQAQ YRIFKAKDGR IIGQTDINFN GGHIEECSCY PNEGKVECVC RDNWTGTNRP  
Newmarket/79             .......... ..I....... .......... .......... .........K .......... .......... .......... .......... ..........  
Fontainebleau/79         .......... ..I....... .......... .......... .........K .......... .......... .......... .......... ..........  
Eurasian 
Sussex/89                ....N..... ..I....... .......... .......... .........K .......... .......S.. .......... ........I. ..........  
Newmarket/2/93           I...N..... ..I.....W. .......... .......... .........K .......... .......S.. .......... ........I. ..........  
Aboyne/05                ....N..... ..I....... .......... .......... .........K .......N.. .......S.. .......... ........I. ..........  
Lincolnshire/06          ....N..... ..I....... .......... .......... .........K .......N.. V......S.. .......... ........I. ..........  
American 
Newmarket/1/93           I...N..... ..I....... .......... .......... .........K .......... .......S.. .......... ........I. ..........  
Kentucky/8/94            I...N..... ..I....... .......... .......... .........K .......... ...H...S.. .......... ........I. ..........  
Clade 1 
Ohio/03                  I...N..... ..I....... .......... .......... .........K .......... V......S.. E......... ........I. ..........  
Lincolnshire/07          I...N..... ..I....... .......... .......... .........K .......... V......S.. .......... ........I. ..........  
Dubai/1/12               I...S..... ..I....... .......... .......... .........K .........K V......S.. .......... ........I. ..........  
Clade 2 
Newmarket/5/03           I...N..... ..I....... .......... ....N..... .........K .......... V......S.. .......... ........I. ..........  
Richmond/1/07            I...N..... ..I....... .......... ....N..... .........K .......... V......S.. .......... ........I. ..........  
East Renfrewshire/2/11   I...N...F. ..I....... .......... ....N..... .........K .......... V......S.. .......... ........I. ..........  
Worcestershire/1/12      I...N..... ..I....... .......... ....N..... .........K .......... V......S.. .......... ........I. ..........  
 
 
                         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                                 310        320        330        340        350        360        370        380        390        400                   
Pre-divergent 
Miami/63                 VLVISPDLSY TVGYLCAGIP TDTPRGEDSQ FTGSCTSPLG SQGYGVKGFG FRQGNDVWAG RTISRTSRSG FEIIKIRNGW TQNSKDQIRK QVIVDNLNWS  
Newmarket/79             I......... .......... .......... .......... N......... .......... .......... .......... .......... ..........  
Fontainebleau/79         I......... .......... .......... .......... N......... .......... .......... .......... I......... ..........  
Eurasian 
Sussex/89                I....S.... .......... .......... .......... NK........ ....T..... .......... .......... .........R ...I......  
Newmarket/2/93           I....S.... .......... .......... .......... NK........ ....T..... .......... .......... .........R ...I..P...  
Aboyne/05                I....S.... .......... .........K .......... NK........ ....T..... ....KI.... ......K... .........R ...I..Q...  
Lincolnshire/06          I....S.... .......... .........K .......... NK........ ....T..... ....KI.... ......K... .........R ...I..Q...  
American 
Newmarket/1/93           I....S.... .......... .......... .......... NK........ ....T..... .......... .......... .........R ...I..P...  
Kentucky/8/94            I....S.... .......... .......... .......... NK........ ....T..... .......... .......... .H.......R ...I..S...  
Clade 1 
Ohio/03                  I....S.... .......... .......... .......... NK........ ....T..... .......... .......... .........R ...I.DP...  
Lincolnshire/07          I....S.... .......... .......... ......N... NK........ ....T..... .......... .......... .........R ...I.DP...  
Dubai/1/12               I....S.... .......... .......... ......N... NK........ ....T..... .......... .......... .........R ...I.DP...  
Clade 2 
Newmarket/5/03           I....S.... .......... .......... .......... NK........ ....T..... .......... .......... .........R ...I.DP...  
Richmond/1/07            I....S.... .......... .......... .......... NK........ ....T..... .......... .......... .........R ...I.DP...  
East Renfrewshire/2/11   I....S.... .......... .......... .......... NK........ ....T..... .......... .......... I........R ...I.DP...  
Worcestershire/1/12      I....S.... .......... .......... .......... NK........ ....T..... .......... .......... .........R ...I.DP...  
 
 
                         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                                 410        420        430        440        450        460        470             
Pre-divergent 
Miami/63                 GYSGSFTLPV ELTKKGCLVP CFWVEMIRGK PEEITIWTSS SSIVMCGVDH KVASWSWHDG AILPFDIDKM  
Newmarket/79             .......... .......... .......... ...T...... .......... RI........ .V........  
Fontainebleau/79         .......... .......... .......... ...T...... .......... RI........ .V........  
Eurasian 
Sussex/89                .......... .......... .......... ...T...... .......... .I........ ..........  
Newmarket/2/93           .......... .......... .......... ...T...... .......... .I........ ..........  
Aboyne/05                .........I .....E.... .......... ...T.T.... .......... .I........ ..........  
Lincolnshire/06          .........I .....E.... .......... ...T.T.... .......... .I........ ..........  
American 
Newmarket/1/93           .......... .......... .......... ...T...... .......... .I........ ..........  
Kentucky/8/94            .......... .......... .......... ...T...... .......... .I........ ..........  
Clade 1 
Ohio/03                  .......... .......... .......... ...T...... .......... .I........ ..........  
Lincolnshire/07          .......... .....E.... .......... ...T...... .......... .I........ ..........  
Dubai/1/12               .......... .....E.... .......... ...T...... .......... .I........ ..........  
Clade 2 
Newmarket/5/03           .......... .......... .......... ...T...... .......... .I........ ..........  
Richmond/1/07            .........I .......... .......... ...T...... .......... .I........ ..........  
East Renfrewshire/2/11   .......... ....R..... .......... ...S...... .......... .I.N...... ..........  
Worcestershire/1/12      .......... ....R..... .......... ...S...... .......... .I........ ..........  
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